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ABSTRACT
Treatment of traumatic bone injuries is actively relying on tissue engineering strategies
for bone repair. In this research, we examined mesenchymal stem cells (MSCs) on
carbon-based biomaterials, with a long-term goal of bone regeneration. MSCs are adultderived cells that can differentiate into osteoblasts, and simultaneously stimulate
osteoprogenitors in bone tissue environments. More specifically, carbon-based
materials such as graphene, provides a bone-specific microenvironment for MSCs to
undergo ossification. However, although the goal is new bone formation, signaling
mechanisms to achieve bone differentiation can vary. Therefore, the over-arching focus
of this research was to evaluate the osteogenic behavior of MSCs in the presence of
graphene materials.
This dissertation contains five chapters. In chapter 1, we reviewed 3D-printing graphene
scaffolds for tissue engineering. However, developing graphene scaffolds first requires
understanding of MSC activity on graphene surfaces. Therefore, chapter 2 examines
MSCs cultured on a low-oxidized graphene substrate, which supported several genes
important to bone differentiation. In chapter 3, we examined the gene expression profile
of MSCs cultured on graphene oxide (GO) and reduced graphene oxide (rGO), the
major graphene derivatives. We found that genetic activity of MSCs was robustly
upregulated on rGO in comparison to GO substrates. Afterwards, we shifted to the in
vivo ovariectomized (OVX) rodent model, which mimics post-menopause osteoporosis.
In chapter 4, we found that MSCs derived from OVX rats lacked normal bone
mineralization in comparison to MSCs derived from healthy rats. RNA sequencing
analysis revealed that several genes important to bone differentiation were not
upregulated in OVX-MSCs. We therefore postulated that osteoporotic-bone injuries
could be restored by delivering healthy MSCs on a graphene scaffold. In chapter 5, we
created a mandible defect in both sham and OVX animals, which was filled with a 3Dprinted rGO-MSC construct. After 60 days, we found similar bone regenerative potential
between sham and OVX animals, suggesting that rGO-MSC scaffolds provides an
optimal signaling environment within osteoporotic bone.
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Overall, this information is a foundation of the cell signaling network between MSCs and
graphene materials. Future models could potentially use graphene materials to prime
MSCs into the bone differentiation pathway prior to in vivo applications.
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CHAPTER I:
3D-PRINTING GRAPHENE SCAFFOLDS FOR TISSUE ENGINEERING
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ABSTRACT
Graphene-based materials have recently gained attention for regenerating various
tissue defects including bone, nerve, cartilage, and muscle. However, graphene
constructs have mainly been studied as 2-dimensional (2D) substrates when biological
organs are within a 3-dimensional (3D) environment. Therefore, developing 3D
graphene scaffolds is the next clinical standard, yet most have been fabricated as
foams which limits control of consistent morphology and porosity. To overcome this
issue, 3D-printing technology is revolutionizing tissue engineering, due to its speed,
accuracy, reproducibility, and overall ability to personalize treatment whereby scaffolds
are printed to the exact dimensions of a tissue defect. However, 3D-printed graphene
scaffolds have surprisingly only begun within the last few years. In this review, we briefly
discuss the different fabrication techniques for 3D scaffolds, the novelty of graphene
materials, and its application for 3D printing in tissue engineering. This information will
help tissue engineering scientists to study graphene-based materials as 3D-printing
candidates for traumatic tissue injuries.
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INTRODUCTION
There is a growing demand to engineer functional tissue using 3-dimensional (3D)
biological substitutes. Tissue engineering is a field composed of many scientific
disciplines including biomedical engineering, cellular molecular biology, material
science, and biochemistry. The concept of tissue engineering evolved in the 1990s
whereby stem cells and materials could be implanted in vivo to restore injured tissues.1
Since all tissues are derived from stem cells, conventional tissue engineering strategies
have centered around stem cell-based therapies. However, preparation of exogenous
stem cells is a process that can take months—between isolation, expansion,
characterization, and ensuring quality control (i.e. lack of viral contamination). Even
then, stem-cell therapies are not FDA approved and have many concerns over
regulation and safety. Alternatively, scaffold materials that both supports a defect and
attracts endogenous stem cells to the injured area is the future of tissue engineering.
Graphene materials have recently gained attraction for engineering new tissues.
However, most graphene studies have relied on 2-dimensional (2D) surfaces, when
native tissues are within a 3-dimensional (3D) environment. Hence, the fabrication of
novel biomaterials (including graphene derivatives) relies on 3D construction, which is
feasible through many techniques, including 3D printing. In this review, we briefly
discuss the different fabrication techniques for 3D scaffolds, the novelty of graphene
materials, and its applications for 3D printing in tissue engineering.

Material Fabrication Techniques
There are several fabrication techniques to produce scaffolds which are categorized as
either conventional or rapid prototyping (as summarized by Eltom et al., 2019). 2
Conventional techniques include electrospinning, solvent casting, leaching, and phase
separation.3-5 However, with conventional techniques there is poor control over
architecture, pore network, and pore size, drawing challenges to consistently reproduce
scaffolds with identical parameters.6, 7 On the other side, rapid prototyping uses
computer software, more commonly known as computer aided design (CAD), which
designs scaffolds for production by a 3D printing machine. Figure 1.1 describes the
steps between software design and the final product of a 3D printed scaffold. The

5
design is then converted into a digital format using a Standard Tessellation Language
(STL) file format. Using the STL file, the software ‘slices’ the design into multiple layers
which are given values that denote how each layer is printed. The next step is G-coding
which communicates to the machine on how to move during printing. These files are
then transferred to a 3D printer and the material of interest is subsequently printed into
a 3D construct. A common 3D printing technique is fused deposition modeling (FDM)
whereby a thermoplastic polymer is melted above its glass transition temperature,
extruded through the printer’s nozzle, and re-solidifies upon cooling on the print bed.8-10
In tissue engineering, fabricating 3D printed scaffolds has gained much popularity due
to its speed, accuracy, reproducibility, and overall ability to personalize treatment
whereby scaffolds are printed to the exact dimensions of a tissue defect. Most recently,
there is new excitement of 3D printing directly into a patient’s body. For example, when
diseased tissues are extracted during surgery, 3D printing technology could directly fill
the open cavity for faster recovery and less pain post-surgery.

Material Properties for Tissue Engineering
Although 3D printing is revolutionizing personalized treatment, the material needed to
print the scaffold is a long-debated topic that depends on the desired tissue source to
be repaired. These materials range anywhere from hydrogels, to nanoparticles, biometals, bio-ceramics, and bio-degradable polymers. There are many material properties
that influence tissue regeneration such as porosity, wettability, stiffness, strength,
elasticity, biodegradability, and cytocompatibility. Materials must withstand water
absorption without rapid deterioration, but yet gradually degrade overtime so that (1)
new tissue can independently function and (2) does not create a permanent implant.
Additionally, many tissues require a 3D porous structure that allows blood vessel
infiltration for constant nutrient transport as cells are building new tissue.11 The optimal
pore size may vary between different tissues, but typically ranges between 100 – 500
µm.12, 13 Thus, fabricating a porous structure is one variable that can be conveniently
controlled by 3D printing technology.
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Finally, tissue engineering materials must demonstrate properties of cytocompatibility,
including cell adherence, cell viability, and stimulation of cell differentiation. Studies
have shown that 3D scaffolds support cytocompatibility better than their 2D control
counterpart.14-17 Overall, testing 3D-printed structures in vitro is a stronger predictor of
tissue reconstruction outcomes before implanting in vivo. Since carbon nanomaterials
are under study for treating multiple tissue defects, the remainder of this review will
specifically focus on graphene materials and its future as a 3D-printed scaffold.

Carbon Nanomaterials
Carbon-based nanomaterials have gained attention for treating various tissue defects. 1820

Nanomaterials refers to extremely small particles (generally 1-100 nm by dimension),

but yet are very strong and light weight. Particles <100 nm Ø can enter cells, while
those smaller than 40 nm Ø can enter the nucleus.21 Intracellular components such as
DNA, RNA, proteins, and lipids control the cell’s behavior and yet are very small
nanometer structures. Therefore, nano-sized materials provide an attractive
environment for optimal cell function.
Graphene Materials
Carbon nanomaterials include fullerenes, carbon nanotubes, nanodiamonds, carbonbased quantum dots, and graphene.22 Of these, graphene is relatively the youngest and
has rapidly emerged as a superstar due to its versatile properties in several industries
from electronics to sporting equipment and medical science. Graphene comes from
graphite, a gray crystalline mineral from rocks of South America, Asia, and North
America. Graphite is easily recognized as the material within pencils, traditionally (but
mistakenly) referred to as “pencil lead”. Graphite’s 3D structure contains millions of
graphene layers that are weakly attached by van der Waals forces. 23 The carbon atoms
are arranged as flat hexagonal rings, with each carbon covalently bonded to three other
carbons. But despite its long-time existence, a graphene monolayer was not isolated
until 2004 by Professor Sir Andre Geim and Professor Sir Kostya Novoselov, University
of Manchester. Since then, graphene materials have been extensively studied in
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engineering several tissues including bone 24-27, cartilage 28-30, nerve 31-33, skin 34-36, and
heart.37-39
However, pristine graphene is hydrophobic (due to hydrocarbon contamination following
air exposure) thereby lacking dispersion in water which raises aggregation/toxicity
concerns when delivered in vivo.40 This limitation has resulted in functionalizing graphite
with hydrophilic groups that contain oxygen. Interestingly, this idea was discovered long
before graphene when Benjamin Brodie oxidized graphite in 1859. 41 Today, the most
common method to oxidize graphite is by the Hummer’s method (a mixture of sulfuric
acid, sodium nitrate, and potassium permanganate). Hereafter, graphite oxide layers
are sonicated in water to exfoliate monolayers of graphene oxide (GO) (Figure 1.2).
Unlike graphene, GO disperses in water and contains hydroxyl, carboxyl, and epoxy
functional groups which allows it to be combined with other polymers or molecules for
therapeutic use.42 Typically, the C:O ratio in GO is 3 to 1.43 However, its exact
composition can vary depending on the graphite source and the method of production.
Therefore, the amount and distribution of oxygen functional groups may be similar, but
not identical between GO sources.44
Other functionalized graphene derivatives include reduced graphene oxide (rGO) which
is an intermediate structure between graphene and GO, since it partially restores some
properties lost during oxidation.6 When GO is chemically reduced, some (but not all) of
the oxygen functional groups are removed (Figure 1.2). In other words, rGO is the result
of reducing the number of oxygen atoms found in GO. Reports estimate that rGO
restores 80% sp2 structure with the remaining sp3 bonds derived from residual oxygen
(C:O = 13:1).8 The reason for deoxygenation is because GO desensitizes the natural
conductivity property of pristine graphene.45 Therefore, rGO is favored for treating
cardiac and neural defects as these tissues generate electrical signals.

3D Printing of Graphene Scaffolds
Many tissue engineering studies have fabricated graphene materials as a 2D cell
culture substrate, with results indicating cell compatibility by enhancing gene/protein
expression, proliferation, and differentiation.46-49 However, a 2D cell culture substrate
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does not mimic the natural 3D tissue microenvironment. Developing 3D graphene
scaffolds is the new standard, but most have been fabricated as foams which limits
control of morphology such as the number of pores, the pore diameter, and the fiber
diameter.50-55 Therefore, it is attractive to 3D print graphene scaffolds, but surprisingly
this progress has only begun within the last few years. The flaky texture of graphene
resembles sawdust particles, and consequently is not a candidate for direct printing.
Therefore, graphene materials must be incorporated within an ink that sustains a 3D
shape upon printing.
Zhu et al., 2015 was one of the first studies to successfully 3D-print a graphene
construct with a microlattice architecture (as shown in Figure 1.3B).56 The intent of this
study was to overcome the challenge of developing a printable graphene-based ink
while maintaining its intrinsic properties (i.e. large surface area, stiffness, etc.). An ink
gel was developed by combining a GO suspension with a silica filler which was loaded
and extruded via the three-axis positioning stage (ABL 9000, Aerotech). The resulting
construct was a porous GO aerogel with a cube like structure. However, it should also
be noted that aerogels are very low-density solids and easily collapse. But nonetheless,
this study showed future potential of 3D printing graphene materials with other polymers
more suitable for tissue engineering scaffolds. For example, Wei et al., 2015 printed
rGO with thermoplastic polymers such as acrylonitrile-butadiene-styrene (ABS) or
polylactic acid (PLA).8 rGO-ABS was prepared in concentrations of 0.4, 0.8, 1.6, 2.3,
3.8, 5.6, and 7.4 wt%. The majority of these concentrations extruded smoothly from the
3D printer (HOF1-X1, China), but 7.4% rGO-ABS clogged the printer’s nozzle. However,
it was noted that a more powerful homogenizing technique could allow more loading of
rGO material. It was also recorded that the glass transition temperature (T g) of pure
ABS alone was ~105.8°C, but shifted to ~110°C with presence of rGO. When printing
any novel material, the correct Tg is necessary so that the material is softened (yet not
melted) for extrusion and subsequent cooling at room temperature.57 Finally, Jiang et
al., 2018 successfully designed a porous GO hydrogel via 3D printing.58 The ink was
prepared by adding CaCl2 into a GO suspension whereby the Ca2+ ions could crosslink
with the functional groups of GO to form a hydrogel. This method prevented any
clogging within the nozzle, defied any collapsing, and maintained its shape upon
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printing. Overall, these studies were the first attempts to directly print a graphene
material using a 3D printing designed system.
More recently, Vijayavenkataraman et al., 2019 printed rGO scaffolds with the specific
intent of engineering neural tissue.59 rGO was mixed within polycaprolactone (PCL), but
the exact concentration was unclear. Scaffolds were fabricated with the
electrohydrodynamic jet (EHD-jet) printing system with the average fiber diameter (~46
µm) and pore size (~125 µm) consistent between both PCL and rGO-PCL scaffolds. As
expected, the rGO-PCL scaffolds demonstrated better electrical conductivity (1.35 ± 0.3
mS/m) in comparison to its PCL control (0.09 ± 0.005 µS/cm). Interestingly, when PC12
cells were seeded, the rGO-PCL scaffolds stimulated more cell proliferation than PCL
alone and supported expression of neural markers such as GAP43, β3-tubulin, and
NF200. Overall, this data showed that rGO can be fabricated as a porous 3D scaffold, is
cytocompatible, and should be further studied in vivo as a neural guide conduit.
Similarly, Seyedsalehi et al., 2020 mixed rGO within PCL at concentrations of either
0.5%, 1%, or 3% and successfully printed 3D scaffolds (strand size = 300 µm, pore size
= 420 µm) with high consistency and repeatability (Figure 1.3A).6 Structures were
printed using the 4th Generation 3D Bioplotter using parameters of: cartridge
temperature (100°C), platform temperature (10°C), pressure (0.6 MPa), and speed (1.4
mm/s). Many material properties were examined including wettability, swelling,
degradation, deformation behavior, compressive modulus, compressive strength, and
cytocompatibility. After 14 days in simulated body fluid, it was found that PCL alone was
hydrophobic, whereas the addition of rGO increased water uptake, swelling, and
accelerated the rate of degradation. Interestingly, 0.5% rGO-PCL scaffolds had the best
mechanical performance with compressive modulus and compressive strength
enhanced by 150% and 185%, respectively. However, increasing rGO content to 1%
and 3% deteriorated mechanical performance as the rGO sheets formed irreversible
aggregates. Finally, all rGO concentrations had no adverse effects on human adipose
derived stem cells and supported cell viability in vitro. Overall, this study supported that
combining small amounts of rGO within 3D printed scaffolds reinforces biomechanical
properties necessary for regenerating tissues and organs.
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Alternatively, other laboratories have coated graphene onto 3D scaffolds to enhance
mechanical strength and cytocompatibility.14,60 For example, Li et al., 2020 first
fabricated 3D printed alginate (Alg) scaffolds before coating with rGO.14 An Alg/Gel ink
was printed using the 3D Bioplotter machine under parameters of room temperature,
platform temperature (5°C), speed (10 mm/s), strand spacing (1.5 mm), and extrusion
air pressure (5 bar). Once printed, the Alg scaffolds were immersed in a GO solution
until a uniform composition was achieved and thereafter reduced in ascorbic acid to
ultimately produce a 3D rGO-Alg scaffold. Porosity size varied from ~100 -1,000 µm due
to multi-angled layers throughout the print. However, it is believed that various pore
sizes are beneficial for tissue engineering as cell signaling is optimal at smaller pore
sizes, while oxygen/nutrient transport is optimal at larger pore sizes. 14, 61, 62 Compared
to Alg-only scaffolds, the coating of rGO increased the modulus by ~4 fold and
demonstrated electrical conductivity. Interestingly, the proliferation of human adipose
derived stem cells on 3D rGO-Alg scaffolds was ~85% higher than cells grown on 2D
rGO substrates. Additionally, expression of alkaline phosphatase (a bone mineralization
marker) was 5 times greater on 3D rGO-Alg scaffolds than on 2D rGO substrates.
Overall, this data supports that rGO is supportive of cell attachment, proliferation, and
osteogenic differentiation. Furthermore, it also supports the necessity of printing 3D
scaffolds that mimic a natural tissue environment.

Graphene and Bone Regeneration
3D construction of graphene scaffolds is the next step for clinical translation in tissue
engineering. This research is important as the last decade of traditional 2D cell culture
systems have shown graphene substrates supports stem cell differentiation into various
lineages. These cell lineages are influenced by the concentration of graphene, its
functionalization, shape, and the stem cell source.63, 64 But more specifically, multiple
laboratories have found that graphene derivatives predominantly supports bone
differentiation.51, 65-80 A PubMed search using the phrase “graphene and bone” had
more than double the publications of graphene and nerve, heart, muscle, and cartilage.
Overall, the mechanical strength of graphene combined with its ability to support
osteogenesis of stem cells, makes it a forefront candidate in bone tissue engineering.
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Although graphene materials have rapidly emerged as a bone substitute, few studies
have examined the mechanisms behind its ability to induce osteogenesis. Some
theories suggest the carbon arrangement imitates an organic bone ECM
microenvironment, attracting cells to attach, self-renew, and differentiate.46
Nonetheless, spontaneous bone differentiation on 2D graphene substrates has been
supported by calcium deposition and upregulation of bone-specific markers (i.e. ALPL,
RUNX2, BMP2, SPP1, BGLAP, BMP2, and COL I). These studies demonstrate the end
result of osteogenic differentiation, but the underlying signaling pathways are still under
investigation. Wei et al., 2017 found that bone marrow-derived mesenchymal stem cells
(BM-MSCs) cultured on GO nanosheets had increased expression of β-catenin, thereby
suggesting involvement of the Wnt/β-catenin pathway during osteogenic
differentiation.81 Xie et al., 2019 found that human dental pulp MSCs cultured on pristine
graphene achieved osteogenesis via the integrin/focal adhesion kinase axis, thereby
signaling SMAD phosphorylation, RUNX2 transcription, and production of SPP1 and
BGLAP proteins.80 Supportively, MacDonald et al., 2021 found that when human
adipose-derived MSCs (AD-MSCs) and BM-MSCs were cultured on low oxygen
graphene (LOG), multiple genes were involved during bone differentiation including
genes related to cell adhesion, extracellular matrix, transcriptional regulation, BMP and
SMAD signaling, growth factors, and angiogenic factors.47 These results were also
encouraging as stem cell therapies derived from adipose tissue are much easier to
obtain than stem cells derived from bone marrow. Therefore, any substrate material,
such as graphene, that can nudge AD-MSCs into the bone lineage, is the preferred
clinical strategy.
Despite this excitement, a major question is determining the best concentration of
graphene that specifically sustains bone differentiation without collateral damage. BMMSCs cultured on GO (0.1 µg/mL) had increased proliferation rates; however, at high GO
concentrations (10 µg/mL), the BM-MSCs shrank and subsequently had reduced cell
proliferation after just 3 days of culturing.81 Similarly, Sun et al., 2021 found that silk
fibroin/nanohydroxyapatite/GO (SF/nHA/GO) scaffolds loaded with urine-derived stem
cells, had reduced osteogenic differentiation when GO concentrations exceeded 0.5%.82
However, a different study found that 0.1% GO (combined with chitosan and
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hydroxyapatite), was an optimal concentration for cell adhesion, proliferation, and
differentiation of MC3T3-E1 cells, a preosteoblast cell line.83 In vivo, this concentration
showed both osteogenic induction and no adverse reactions in a rat cranial defect model.
Overall, before graphene is clinically applied as a bone biomaterial, it is very important to
clearly understand the optimal concentration for all derivatives including pristine
graphene, GO, and rGO. Additionally, the concentration could also change based on the
stem cell source, the shape and surface topography, and when the graphene source is
combined with other polymers or drugs.
Despite this ongoing challenge, graphene materials have versatile ways in influencing
bone regeneration. For example, graphene can indirectly support bone regeneration as
a delivery vehicle that controls the release of potent BMP2 growth factors.84-87 This helps
to minimize the side effects of BMP2 reagents, but yet still provide a sustained stimulation
of stem cells over time. GO was also used as a drug delivery platform to achieve a steady
release of baicalin, a flavonoid compound widely used for both its osteoinductive and antiinflammatory properties.88 The surface area of graphene materials allows the
immobilization of growth factors for targeted drug delivery that not only influences bone
regeneration, but other tissues such as nerve and cartilage. 29, 64, 89-91 In other strategies,
Hou et al., 2020 studied a 3D-printed graphene-PCL scaffold to conjunctively induce both
cytotoxicity of Saos-2 cells (a human osteosarcoma cell line) and attract new bone
regeneration. It was proposed that the gradual release of graphene could induce
apoptosis of cancer cells, while the remaining PCL layers provided the biomechanical
environment to sustain the recruitment of healthy stem cells. 63 Overall, graphene
materials have versatile properties for supporting bone regeneration including as a direct
stimulator of new bone material, a delivery vehicle for other pharmaceutics, or targeting
cancers of the bone.

Toxicity Challenges of Graphene Materials
Despite the excitement of graphene materials and its use as a 3D scaffold for tissue
engineering, its therapeutic use is still a novel idea and has yet to face a human clinical
trial. As with any new substance, the primary question to address will always be safety.
Information regarding toxicity of graphene is still uncertain, including any carcinogenic
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potential. Yet, medical research has raced to examine its physiological effects for
various diseases.
There are a growing number of in vivo reports regarding toxicity of graphene
materials.92-97 An early study described by Yang et al., 2010 evaluated GO sheets
coated and functionalized with polyethlene glycol (PEGylated nanographene sheets or
NGS-PEG) in mouse tumor models.98 After 40 days, systematic injection of NGS-PEG
(20 mg/kg) specifically targeted the tumor site with no signs of toxicity or accumulation
in the kidney, liver, heart, spleen, intestine, or lungs. Interestingly, when NGS-PEG was
combined with photothermal therapy, the tumors were completely ablated, suggesting
graphene’s potential for complementing current cancer treatments. However, it is
important to note there was no control for NGS only, which may have had different
toxicity outcomes.
Wang et al., 2011, evaluated GO toxicity in mice after 30 days of exposure to one of
three concentrations: 0.1 mg, 0.25 mg, or 0.4 mg.99 Results showed no mortality of mice
exposed to 0.1 mg or 0.25 mg of GO. However, 4 of 9 mice died following GO injection
at 0.4 mg. Histopathology results found GO conglomeration in the lung tissues, thus
resulting in airway blockage and subsequent suffocation. When comparing lung tissues
of all treatment groups, the mice exhibited a dose-dependent series of granulomas after
just 7 days of exposure. In other words, increasing GO concentration severely
increased toxicity reactions of the lungs. Overall, these results suggested that GO
exposures could promote lung diseases.
A similar study from a separate laboratory also examined GO toxicity in mice following a
low dose (1 mg/kg body weight) and a high dose (10 mg/kg body weight) via IV
injection.100 After 14 days, the 1 mg/kg dose of GO had no pathological changes in all
organs tested (lungs, liver, spleen, and kidney). However, at 10 mg/kg, there was a high
accumulation of GO in the lungs with pathological changes (i.e. granulomatous lesions,
pulmonary edema, inflammatory cell infiltration, and fibrosis). The authors concluded
that GO was biocompatible in most tissues, but higher dosages draws concern for
abnormal changes within lung tissues.
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With growing pulmonary toxicity concerns, Singh et al., 2012 compared the lungs of
mice injected with either GO or graphene that was functionalized with amine groups (GNH2).101 After 15 min., GO (250 µg/kg) stimulated vascular occlusion in lung tissue,
while animals treated with G-NH2 (250 µg) had no signs of any occlusive pathology and
instead demonstrated normal, healthy lung tissue. It was concluded that G-NH2 is not
pro-thrombotic and is a safe graphene derivative, unlike other variations of graphene
materials.
Schinwald et al., 2012 evaluated the risk of graphene nanoplatelets (GP) (average
thickness of ~10 nm) following either inhalation or intrapleural injection in mice. 102 For
inhalation, 50 µg of GP was added onto the tongue and held until at least 2 full breaths
were completed. After 24 hr, granulomatous lesions were present in the bronchiolar
lumen of mice exposed to GP, but normal lung pathology was observed in both the
vehicle and carbon control groups. Additionally, there was an increase of the total
number of inflammatory cells (i.e. neutrophils, esoinophils) in the lavage fluid, and
continued to show an inflammatory response one-week post-exposure. Secondly, an
intrapleural injection of GP (5 µg) resulted in particle aggregations in pleural
macrophages, indicating frustrated phagocytosis, an elevation of pro-inflammatory
cytokine markers, and pleural thickening of the chest wall. Overall, the authors
concluded that GP imposes a risk to the respiratory system, but acknowledged that the
layer thickness is a key factor, and should be manufactured small enough that allows
phagocytosis by macrophages.
Most recently, Tabish et al., 2018 studied the toxicity of graphene nanopores (GNP)
after a single IP injection or multiple injections (total of 14) over 27 days at doses of 5
mg/kg or 15 mg/kg in a rat model.21 All doses (whether low or high, single or multiple)
showed concerns in all tissues tested (liver, kidney, heart, small intestine, brain, testis,
and lung), including tumor development within neural tissue of the brain. The
pathological changes were presumably due to accumulation and low clearance of GNPs
in the rat. Overall, more long-term in vivo studies are necessary to minimize adverse
effects of graphene materials. The proper dosage and administration route must be
carefully examined before any introduction of graphene materials in the clinic.
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Future Perspective and Conclusions
Conventional strategies of repairing tissue defects have relied on exogenous stem cells
and 2D substrates. However, stem-cell based therapies have many limitations with
future strategies turning to 3D structures that both supports and attracts cell
differentiation within the injury site. Graphene, a novel biomaterial is under thorough
research for repairing various tissues such as bone, cartilage, nerve, and heart.
However, in vitro work of graphene has mainly been studied as a 2D monolayer or a 3D
foam, whereby scaffold morphology is poorly controlled. With the revolution of 3Dprinting technology, questions have asked whether graphene scaffolds can be 3D
printed. Currently, there is a paucity of studies that have attempted 3D-printed graphene
scaffolds for tissue engineering. These studies have mainly surfaced in the last few
years, but it is expected that more developments will evolve in the future. Finally, 2Dgraphene substrates have predominantly been studied in supporting new bone
differentiation. Therefore, 3D-printed graphene scaffolds is the next step for clinical
application in bone tissue engineering. However, understanding the optimal
concentration of all graphene derivatives that balances both bone differentiation and
minimizes toxicity is necessary prior to transplantation. Overall, there is great
excitement over 3D-printed graphene scaffolds, but much work is necessary before
standardization within tissue engineering.
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APPENDIX

Figure 1.1. The process of a computer-controlled 3D-printing system.
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Figure 1.2. The structure of graphene, graphene oxide, and reduced graphene
oxide.

25

A

B

Figure 1.3. Images of 3D-printed graphene scaffolds. (A) Images of each printed layer
of a PCL-rGO scaffold, adapted by Seyedsalehi et al., 2020. (B) Image of a 3D-printed
GO aerogel with a micro lattice architecture, adapted by Zhu et al., 2015.
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Table 1.1 Summary of 3D-Printed Graphene Studies. GO (graphene oxide); rGO (reduced graphene oxide); ABS
(Acrylonitrile-butadiene-styrene); PLA (Polylactic acid); PCL (polycaprolactone).
Author, Year

Graphene
Source

Polymer

3D-Printer Model

Printing Parameters

Overall Purpose

Zhu, 2015

GO

Silica

3-axis positioning
stage (ABL 9000,
Aerotech)

N/A

To demonstrate a 3D-printing
strategy for graphene

Wei, 2015

Jiang, 2018

Vijayavenkataraman,
2019

Seyedsalehi, 2020

Hou, 2020

rGO

ABS
Or
PLA

HOF1-X1

rGO-ABS
Chamber Temp: 230°C
Platform Temp: 80°C Nozzle:
130°C
Speed: 20 mm/s
rGO-PLA
Chamber Temp: 190° Platform
Temp: 60°C
Nozzle:130°C
Speed: 20 mm/s

GO

GO was
crosslinked with
Ca2+ ions to form
a hydrogel

TH-206H

Room Temp
Pressure: 2-3 bar
Speed: 4-10 mm s-1

rGO

PCL

Electrohydrodynamic
jet (EHD-jet)

rGO

Graphene

PCL

PCL

4th Generation 3D
Bioplotter

3DDiscoveryTM
Evolution

N/A

To demonstrate graphene is
3D printable

To enhance the functionality
of 3D-printed graphene
structures

To create a nerve guide
conduit for neural
regeneration

Temp: 100°C
Platform Temp: 10°C
Pressure: 0.6 MPa
Speed: 1.4 mm/s

To evaluate printability,
mechanical, and biological
properties

Temp: 90°C
Screw Rotation Velocity: 8 rpm
Deposit Velocity: 12 mm/s
Pressure: 6 bar

To create a scaffold that
targeted both osteosarcoma
and recruited healthy stem
cells for bone regeneration
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CHAPTER II:
GENETIC PROFILING OF HUMAN BONE MARROW AND ADIPOSE
TISSUE-DERIVED MESENCHYMAL STEM CELLS REVEALS
DIFFERENCES IN OSTEOGENIC SIGNALING MEDIATED BY
GRAPHENE
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ABSTRACT
Background: In the last decade, graphene surfaces have consistently supported
osteoblast development of stem cells, holding promise as a therapeutic implant for
degenerative bone diseases. However, until now no study has specifically examined the
genetic changes when stem cells undergo osteogenic differentiation on graphene.
Results: In this study, we provide a detailed overview of gene expressions when
human mesenchymal stem cells (MSCs) derived from either adipose tissue (AD-MSCs)
or bone marrow (BM-MSCs), are cultured on graphene. Genetic expressions were
measured using osteogenic RT2 profiler PCR arrays and compared either over time (7
or 21 days) or between each cell source at each time point. Genes were categorized as
either transcriptional regulation, osteoblast-related, extracellular matrix, cellular
adhesion, BMP and SMAD signaling, growth factors, or angiogenic factors. Results
showed that both MSC sources cultured on low oxygen graphene surfaces achieved
osteogenesis by 21 days and expressed specific osteoblast markers. However, each
MSC source cultured on graphene did have genetically different responses. When
compared between each other, we found that genes of BM-MSCs were robustly
expressed, and more noticeable after 7 days of culturing, suggesting BM-MSCs initiate
osteogenesis at an earlier time point than AD-MSCs on graphene. Additionally, we
found upregulated angiogenic markers in both MSCs sources, suggesting graphene
could simultaneously attract the ingrowth of blood vessels in vivo. Finally, we identified
several novel targets, including distal-less homeobox 5 (DLX5) and phosphateregulating endopeptidase homolog, X-linked (PHEX).
Conclusions: Overall, this study shows that graphene genetically supports
differentiation of both AD-MSCs and BM-MSCs but may involve different signaling
mechanisms to achieve osteogenesis. Data further demonstrates the lack of aberrant
signaling due to cell-graphene interaction, strengthening the application of specific form
and concentration of graphene nanoparticles in bone tissue engineering.
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BACKGROUND
In the United States, there are approximately 1 million new cases of severe bone
defects that require medical intervention. Traditionally these defects are filled with
autologous bone grafts, in which bone removed from the hip or ribs is implanted into the
defected area. Unfortunately, this method causes many limitations as the procedure
alone is highly invasive, increases the risk of infection, causes donor site morbidity, and
overall is not appropriate for geriatric patients. An alternative and extensively
investigated medical strategy is bone tissue engineering. Bone tissue engineering
requires viable or osteoprogenitor cells and natural/synthetic biomaterials which
together are used in the fabrication of novel scaffold constructs [1]. Biomaterials
developed for bone are manufactured with specific functions: (1) to deliver and home
stem cells to the injury site, (2) to induce osteoblast differentiation of the externally
delivered osteoprogenitors cells, (3) to induce osteoblast differentiation of the
endogenous progenitor cells, and (4) should be mechanically strong, flexible, and
gradually resorb as new bone is formed over time.
Since graphene’s discovery in 2004, graphene-based nanocomposite scaffolds have
gained significant appreciation in biomedicine, specifically bone tissue engineering.
Graphene is a single isolated layer of graphite, having a two-dimensional structure
consisting of carbon atoms orchestrated as hexagonal rings. It has been called “the
wonder material” due to its superthin, yet super-strong and flexible features. In addition
to single layer graphene, few-layer graphene can also be utilized for many of the same
applications that single-layer graphene has been touted. Many variations of graphene
have been developed that differ largely on the oxygen content – from pristine with little

32
to no oxygen in the carbon network to graphene oxide (GO) with the highest amounts of
incorporated oxygen. There are many terms that can refer to variation in the chemical
makeup, including reduced graphene oxide (rGO) and highly reduced graphene oxide
(hrGO). These modifications are necessary for many applications since the pristine
form of graphene is hydrophobic and consequently, cannot be dissolved or readily
dispersed in water or bodily fluids. Aside from simple oxygen functionalization, many
other functionalities and treatments can be incorporated to make graphene highly
dispersible and less toxic [2-5]. We have coined distinct terms for the oxygen
functionalized graphene based on the oxygen content, i.e. low and high oxygen content
graphene as LOG and HOG, respectively [6, 7].
Graphene was first recognized to be biocompatible and a potential bone biomaterial in
2010 after recognizing that human osteoblasts and mesenchymal stem cells (MSCs)
adhered and proliferated on graphene better than on silicon dioxide substrates [8].
Since then, multiple laboratories (including ours) have recognized graphene and its
derivatives as valid osteoinductive and osteoconductive nanomaterials in vitro and in
vivo [9, 10]. Our research group has demonstrated that a low-oxygen content graphene
(LOG) material was cytocompatible and supported the adherence, proliferation and
osteogenic differentiation of goat bone marrow derived MSCs (BM-MSCs) in vitro [9].
We then confirmed the osteoinductive and osteoconductive potential of LOG with goat
adipose derived MSCs (AD-MSCs) in vivo [10]. Likewise, we most recently
demonstrated that LOG exhibited similar effects on human AD-MSCs in vitro, i.e. MSCs
underwent osteogenic differentiation without any chemical induction. Human MSCs
exposed to graphene surfaces expressed specific integrin heterodimers and the
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corresponding ECM proteins, suggesting that the structure and topography of LOG
surface potentially induces the expression of bone – specific ECM and thus, promotes
MSCs to undergo osteogenic differentiation [11].
Even though graphene-based nanomaterials are being used in bone tissue engineering
and their biological role in osteoblast differentiation of MSCs has been demonstrated in
multiple studies, in vitro and in vivo, the signals that are triggered i.e. the knowledge of
the signal transduction pathways that the cells undergo during this process is limited
[12, 13].
Adult MSCs can be isolated from a variety of tissues including, bone marrow, adipose
tissue, dental pulp, umbilical cord blood, Wharton’s jelly, and the placenta. Even though
bone marrow and adipose tissue are the most commonly used tissue sources of MSCs,
their efficacy in regenerative medicine is varied. This is primarily due to the donor-todonor variation as well as the variations in isolation and in vitro cell culturing protocols of
expansion [14-16]. The application of either bone marrow or adipose tissue – derived
MSCs in bone tissue engineering can be further affected by the interaction between
MSCs and the nanomaterials used. Hence, in order to assess the efficacy of
nanomaterial/cell constructs and to improve the fabrication of the nanomaterials, it is
important to evaluate differences in cell signaling in presence of the nanomaterials.
This study was carried out to understand the genetic expressions that graphene
regulates on human MSCs i.e. to identify molecular targets that specifically
communicate osteogenic differentiation of MSCs. The study design also provided us
with the opportunity to compare and contrast the osteogenic response between bone
marrow and adipose tissue – derived MSCs. All graphene and MSC studies report
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conclusions from single reactions of osteoblastic markers [17-19], but this method
provides minuscule insight on how graphene nanomaterials influence cell behavior
during osteogenesis. Therefore, the objective of this study was to measure and
compare changes in gene expression during osteogenesis of human MSCs derived
from adipose tissue and bone marrow on a LOG surface. Based on previous literature
and data from our laboratory, we hypothesized that using osteogenic focused arrays
and monitoring changes in osteogenesis over a specific time period, we will be able to
evaluate the key pathways that MSCs go through in presence of functionalized form of
graphene.

MATERIALS AND METHODS
Tissue Procurement, Cell isolation and Characterization
Human adipose tissue – derived MSCs were isolated, characterized and cryobanked as
described earlier [11]. Prior to cell isolation, patient consent was obtained and approved
by an IRB protocol at the University of Tennessee Medical Center in Knoxville. Adipose
tissue was collected from patients undergoing pannulectomies. Following cell
expansion, human adipose-derived MSCs (AD-MSCs) were confirmed for cell
morphology, protein markers, and trilineage differentiation, as described earlier [11, 20].
Human bone-marrow derived MSCs (BM-MSCs) were commercially purchased from
American Type Culture Collection (ATCC) (Manassas, VA). Cells were expanded and
cryopreserved as per ATCC’s recommendations. MSCs were confirmed for their
adherence to tissue culture plastic and ability for tri-lineage differentiation in vitro.
Cells from passages 2-6 were used in all experiments described.
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Preparation and Characterization of Graphene
Processing conditions
Pristine graphene was purchased commercially from Angstron Materials (Dayton, Ohio)
and oxidized within an acidic mixture (6:2:3 ratio of sulfuric acid, nitric acid, and water)
as described earlier [6, 10]. The final product was a low-oxygen functionalized form of
graphene (LOG) with approximately 6-10% oxygen content and was confirmed to be the
form used in previous studies [6, 10]. LOG was dispersed in ethanol/water by
sonication. Aliquots of the dispersion were used to coat the dishes for cell culture.
Deposition of graphene
Non-tissue cultured treated dishes were coated with LOG to produce uniform surfaces
with very little exposed plastic. For all experiments, the LOG concentration was 0.2
mg/cm2 of dish surface.
Surface topography
Surface roughness/topography was investigated using atomic force microscopy (AFM).
A Bruker Dimension AFM using a Budget Sensors Tap300Al-G tip (300 kHz and 40
N/m) in tapping mode. Random spots were chosen for analysis on a 100 mm petri dish
and scan sizes of 50 mm x 50 mm were collected. An average of 7 spots and standard
deviation was determined. NanoScope Analysis 1.5 (Bruker) software was used to
analyze the surface images to determine average roughness (Ra) and root-meansquare (Rq).
Osteogenesis and mineralization of MSCs
AD-MSCs and BM-MSCs were grown to 70-80% confluency in growth media (DMEM
F12+10%FBS+1%penicillin-streptomycin-antimycotic) and incubated in an atmosphere
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of 5% CO2 at 37°C. For experimental conditions, cells were harvested with 0.05%
trypsin and seeded at 1 X 105/well of a 12 well plate and 1 X 106/100 mm cell culture
dish coated with LOG. Cells were cultured on LOG for either 7 or 21 days and were
maintained in growth media without any osteo-differentiation inducers throughout the
study. At specified time points, cells were either stained with Alizarin red and
quantitated as reported earlier [11] or collected for RNA experiments (described below).
To ensure that AD-MSCs generated in our lab and commercial BM-MSCs retained their
osteogenic potential under standard conditions, cells were cultured on tissue culture
polystyrene surface in presence of osteogenic induced medium (growth media
supplemented with 10 nM β-glycerophosphate, 100 nM dexamethasone, and 155 µM
ascorbic acid). Osteogenesis was confirmed by Alizarin red staining and quantitation as
previously described [11].
RNA Isolation
Cells were detached from LOG with 0.05% trypsin for approximately 40 min. followed by
centrifugation. A cell pellet was combined from two-100 mm LOG coated dishes to
ensure the RNA quantity was sufficient for triplicate PCR reactions. Total RNA was
isolated using an RNeasy® Mini Kit following the manufacturer’s instructions (Qiagen,
Germantown, MD, #74104). To measure RNA purity and quantity, samples were
loaded onto a Take3 plate, and read on Epoch microplate spectrophotometer (BioTek
Instruments, Winooski, VT) with Gen5 version 2.09 software. The 260/280 nm
absorbance ratio determined RNA purity and was considered optimal at approximately
2.0. RNA 6000 Nano Kit and the 2100 Bioanalyzer system was used to evaluate the
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integrity as per the manufacturer’s recommendations (Agilent Technologies, Santa
Clara, CA) [21].
Human Osteogenesis PCR Array
RT2 Profiler PCR Human Osteogenesis Array (Qiagen, Hilden, Germany, #PAHS-026Z)
was used to evaluate differentially expressed genes from AD-MSCs and BM-MSCs
cultured on LOG. 1 µg of RNA was reversed transcribed to cDNA with a RT2 First
Strand Kit (Qiagen, Hilden, Germany, #330401). The cDNA was added into a RT 2
SYBR Green Mastermix (Qiagen, Hilden, Germany, #330524) before loading 25 µL ( ̴
10.4 ng) per well. cDNA synthesis and PCR reactions were performed according to the
manufacturer’s recommendations [22].
Statistical Analysis
Gene expressions from CT values were analyzed using Qiagen Gene Globe software to
determine the relative fold change (https://geneglobe.qiagen.com/us/analyze/). In the
first analyses, gene expression data obtained from AD-MSCs cultured on tissue culture
polystyrene surface in presence of osteogenic induced medium (growth media
supplemented with 10 nM β-glycerophosphate, 100 nM dexamethasone, and 155 µM
ascorbic acid) for 21 days was set as the control. MSCs cultured on the LOG surface
without the differentiation cocktail for 21 days was designated as the test group.
Thereafter, all comparisons were carried out between the AD and BM – MSCs cultured
solely on the LOG surface.
To evaluate cell signaling on LOG surface, we compared the changes in gene
expression for each cell type between days 7 and 21. Expression at day 7 was set as
the control and day 21 was designated as the test group. Subsequently, the two cell
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types were compared at each time point, with AD-MSCs set as the control group and
BM-MSCs as the tested group. All comparisons were normalized using β-2
microglobulin (B2M) and glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) as the
housekeeping genes. Data is shown from triplicate experiments, with fold changes
statistically significant at p < 0.05.
Cytoscape analyses of potential protein targets
Genes of interest were imported from the appropriate tables into Cytoscape software
(https://cytoscape.org/) containing a basal nodal network derived from the updated
BioGrid data set for Homo sapiens (https://thebiogrid.org/). The complete network was
then filtered based on the target genes resulting in the input gene set nodes with
residual connective line elements from the basal map. Genes were then sorted based
on associated functional group and graphed onto propellor plot diagrams depicting the
up and downregulated candidates for both experimental sample comparisons. Gene
sets displayed in propellor plots serve to demonstrate the comparative difference in
gene expression and thus, can be translated into protein-protein interactions for these
two experimental groups as compared to a common control.
Cytoskeletal organization and expression of ECM proteins
Cytoskeletal organization and morphology of BM-MSCs were assessed by evaluating
the pattern of F-actin staining using previously reported methods [11]. The expression
patterns of ECM proteins corresponding to the gene targets identified for the BM-MSCs
were assessed qualitatively by immunofluorescence detection assays. The
assessments were made during cell attachment (i.e within 24 hr of seeding) and
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osteogenic differentiation (21 days after seeding) Fibronectin 182, and collagen I, were
evaluated as described earlier [11].

RESULTS
Graphene nanomaterials display 6-10% oxygen content
Graphene surfaces have been extensively characterized and reported in previous
publications by [6, 7]. The material is distinct from the commercially available forms of
pristine graphene and graphene oxide (GO) in oxygen content. It may share similar
characteristics with reduced-GO or highly reduced-GO, however, we use the term lowoxygen graphene (LOG) since it is produced directly from commercially obtained
pristine graphene powder, and not via the reduction of GO.
LOG preparations were consistent with that reported earlier, and contain 6-10% oxygen
content, with trace (<0.5%) amounts of sulfur and nitrogen [9, 10]. The oxygen moieties
are distributed within the hydroxyl, carbonyl, ether, and carboxyl groups as reported in
functionalized graphene with higher oxygen content, such as GO [6]. In addition to the
surface chemistry of LOG, surface roughness, which is an important aspect for cell
adhesion/attachment was evaluated [23, 24]. Figure 2.1 displays the root mean squared
(Rq) and average (Ra) roughness values as determined from atomic force microscopy
(AFM). The images collected from AFM show a rough surface topography providing
numerous sites for possible cell attachment. Data is consistent with that reported earlier
[6, 11].
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Human adipose tissue and bone marrow – derived MSCs display similar
osteogenic behavior on LOG surface
We have previously reported that human and goat adipose tissue – derived MSCs
undergo spontaneous osteogenesis on LOG without any chemical induction [9-11]. We
have also demonstrated that goat adipose tissue and bone marrow - derived MSCs
undergo osteogenesis using two distinct signaling pathways [25]. In view of these data,
we evaluated and compared the osteogenic differentiation and mineralization of human
BM-MSCs to AD-MSCs on LOG surfaces using Alizarin red staining and quantitation
(Figure 2.2). The calcium content as judged by Alizarin red staining was significantly
greater in human BM-MSCs seeded on LOG surfaces relative to the cells on the tissue
culture polystyrene surface (p < 0.0001). Interestingly, this upregulation was similar to
that reported earlier for human AD-MSCs [11] and was observed in the absence of any
osteogenic inducers. Calcium content was enhanced (p < 0.0025) when osteogenic
inducers were added to the media. Results suggest that irrespective of the source, the
LOG surface induces similar accumulation of calcium in both the adipose tissue and
bone marrow – derived MSCs in vitro.
Surprisingly, in presence of the differentiation media + LOG, there was a decrease in
the calcium content relative to the cells on tissue culture polystyrene surface. The
reason for this outcome is unknown, and is beyond the scope of this study. Based on
published literature, dexamethasone, beta glycerophosphate and ascorbic acid regulate
several signal transduction pathways and hence, this effect should be investigated in
future studies [26]. Therefore, in the current study, we sought to identify the molecular
targets involved in LOG - mediated stem cell signaling without osteogenic inducers. In
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the experiments described below, cells were maintained in growth media alone without
any supplementation of osteogenic reagents.
High quality RNA was obtained from MSCs
We harvested MSCs from LOG using trypsin, with longer than normal incubation time of
about 40 min. As a result, we evaluated the RNA quantity and quality prior to PCR
analyses. Electrophoresis of total RNAs from AD-MSCs and BM-MSCs in presence of
LOG for both 7 and 21 days showed no degradation and intact ribosomal subunits, 18S
and 28S bands (Figure 2.3A, B). RNA quality was measured by RNA integrity number
(RIN) ranging from 1 – 10, with RIN < 6 considered as a low quality sample [27]. An
electropherogram confirmed high quality RNA with RIN values > 9.0 at both time points
for both cell types (Figure 2.3C-F.).
Focused arrays to evaluate graphene - mediated differentiation
Osteogenesis is a complex signaling pathway coordinated by multiple gene and protein
targets that mediate osteoblast differentiation of stem cells. Therefore, to understand
osteogenic signaling stimulated by graphene, we evaluated gene expression patterns in
human AD-MSCs and BM-MSCs using human osteogenesis focused PCR arrays
(Qiagen, Hilden, Germany, #PAHS-026Z). These 96 well-arrays are coated with primers
that target 84 genes of interest, 5 housekeeping genes for data normalization, and 7
controls to evaluate human genomic DNA contamination, performance of reverse
transcription, and positive PCR control reactions. Genes of interest could be classified
into the following major categories: transcriptional regulation, osteoblast-related,
extracellular matrix markers, cellular adhesion, BMP and SMAD signaling, growth
factors, and angiogenic factors. In addition to the above targets, there are other genes
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included in these arrays which potentially have minor roles in osteogenesis, and hence,
do not fit into the above categories.
As described earlier, expression profiles of ALPL, BGLAP, and RUNX2 during
osteogenesis are commonly used as indicators of cell differentiation and hence, are
typically evaluated using single gene PCR reactions following Alizarin red staining [1719]. Therefore, we examined these gene expressions between human AD-MSCs
cultured on LOG in absence of osteogenic differentiation reagents to MSCs cultured on
tissue culture substrate in presence of differentiation reagents at day 21. Gene
expression on tissue culture substrate was set as the control and that on the LOG
surface was set as the test group (Figure 2.4). There was a significant (P<0.05)
increase in the expression of ALPL and BGLAP in cells cultured on LOG, confirming
osteogenesis under the media conditions described above. RUNX2 was not statistically
different on LOG, thereby suggesting the expression levels are similar across these
comparisons. To understand and compare the osteogenic signaling mediated by LOG
on human AD-MSCs and BM-MSCs, all further comparisons were performed on cells
cultured on the LOG surface only.
Percent of differentially expressed genes suggest early changes in BMMSCs
Gene expressions patterns of AD-MSCs and BM-MSCs cultured on LOG were over
time (day 7 set as control to day 21 set as the test group) within each cell type.
Subsequently the patterns were compared between the two cell lines at each time point,
thus, resulting in a total of 4 comparisons. Differentially expressed and significantly
different genes (p<0.05) are reported and described in sections below. Over time, the
percentage of significantly expressed genes was consistent in both cell types.
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Comparisons showed that 61-62% of the genes analyzed changed statistically with 3743% being upregulated while only 19-24% were downregulated (Figure 2.5A),
complementing the osteogenic response of MSCs on LOG. Interestingly, when day 7
results were compared between the two cell types, 60% of genes were upregulated in
BM-MSCs while only 13% were downregulated (Figure 2.5B), suggesting upregulation
of a higher number of gene targets in BM-MSCs at an earlier time point. Comparatively,
at day 21 only 45% of genes were upregulated in BM-MSCs while 23% of genes were
downregulated. Across all comparisons, ˂ 10% of genes were unconfirmed, possibly
due to low expression or lack of primer annealing, and hence were not detected.
Distinct transcription factors control osteogenesis of MSCs
We examined the expression of four genes, DLX5, RUNX2, SOX9, and SP7 known to
control stem cell fate (Table 2.1). As shown, RUNX2 was significantly upregulated in
AD-MSCs, while SOX9 and SP7 were downregulated, suggesting RUNX2 to be the
master regulator in AD-MSCs. Comparatively, in BM-MSCs, all genes were
downregulated. Interestingly, when BM-MSCs were compared to AD-MSCs, all
transcription factors were upregulated at both time points (Table 2.2). The fold changes
at day 7 were comparatively more robust to that observed at day 21, suggesting the
involvement of all transcription factors triggering osteogenesis at an early time point in
BM-MSCs.
Upregulation of osteoblast-related genes confirm osteogenesis in MSCs
Osteoblast differentiation of MSCs is evidenced by the expression of cell - specific
markers. We examined the expression of 4 genes, ALPL, BGLAP, PHEX, and SPP1,
commonly used as markers of osteogenesis (Table 2.1). As shown, ALPL, BGLAP
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(osteocalcin), and PHEX were upregulated in AD-MSCs while SPP1 was
downregulated. Comparatively, in BM-MSCs, in addition to ALPL and PHEX, SPP1 was
also upregulated, suggesting osteogenesis within 21 days in both cell types. When BMMSCs were compared to AD-MSCs results were very interesting. Only BGLAP was
significantly upregulated at day 7, whereas, at day 21 all genes were downregulated
with the exception of SPP1 (Table 2.2), suggesting osteogenesis of BM-MSCs at a time
point earlier than day 21.
ECM targets support cell adhesion and differentiation
When cells undergo osteoblast differentiation in both the presence and absence of
nanocomposite materials, they express ECM in the form of organic and inorganic
molecules. ECM proteins have important roles in cell adhesion and differentiation. ECM
proteins trigger signal transduction pathway(s) leading to their differentiation to specific
lineages. Once the MSCs are triggered towards differentiation, ECM proteins support
the adhesion of the differentiated cells to the substrate, and hence, are required
throughout their development. The ECM genes exist as families coding for the various
isoforms of the proteins, each form contributing to its function. Here we examined the
expression of specific ECM genes including those coding for collagen, fibronectin, and
proteoglycan (Tables 2.1, 2.2). In AD-MSCs, predominantly all genes tested including
BGN, COL3A1, COL14A1, COL15A1 and FN1 were upregulated while only COL1A2
was downregulated. Comparatively, in BM-MSCs, all genes were upregulated, with the
fold changes much higher than that observed in AD-MSCs. Interestingly when ADMSCs were compared to BM-MSCs at day 7, all genes except COL3A1 and COL15A1
were upregulated (Table 2.2). Taken together, these data suggest that the specific
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genes encoding ECM proteins support the adherence and osteogenesis of MSCs from
both the sources.
Relatively robust upregulation of genes encoding for cell adhesion proteins
MSCs adhere to a given surface and express ECM, and subsequently relay
extracellular signals to the nucleus for osteogenic differentiation and communication.
MSCs are adherent cells and hence, cell adhesion proteins are required for the
attachment and cell development. In this study, 7 cellular adhesion genes were
examined (Table 2.1). In AD-MSCs, ICAM1, ITGA1, and VCAM1 were all upregulated
while only ITGA2 and ITGB1 were downregulated. Similar patterns of expression were
observed in BM-MSCs with upregulation of CDH11, ICAM1, ITGA1, ITGA3, and
VCAM1, and downregulation of only ITGA2 and ITGB1. Comparatively, when AD-MSCs
were compared to BM-MSCs, CDH11, ITGA1, ITGA2, ITGA3, ITGB1 were all
upregulated at day 7. Similar expression patterns were observed at day 21, with the
exception of ITGA2. Noteworthy is the 482.15- and 1376.38-fold upregulation of
VCAM1 at days 7 and 21, respectively (Table 2.2). Results confirm that LOG surface
provides an optimal substrate for cells to adhere, communicate, differentiate, and
maintain their function.
BMP/SMAD – mediated osteogenesis in MSCs
BMP-SMAD signaling is one of the major pathways that the cells use when they
undergo osteoblast differentiation. BMP and the SMAD families of genes consist of
multiple isoforms, majority of which were represented in these arrays. We examined 4
BMPs, 4 BMP receptors (BMPRs) and 5 SMAD isoforms (Table 2.1). In AD-MSCs, only
BMP4 and BMPR2 were upregulated while BMP6 was downregulated. Similarly, all
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SMAD isoforms including, SMAD2, SMAD3, and SMAD5 were upregulated suggesting
that osteogenesis is potentially mediated by BMP/SMAD signaling. Comparatively, in
BM-MSCs, only BMP4, BMPR1A and BMPR1B were upregulated, while BMP2, BMP6
and BMPR2 were downregulated. Of the SMAD genes tested in BM-MSCs, only
SMAD3 was upregulated while SMAD1, SMAD4, and SMAD5 were downregulated.
Interestingly when AD-MSCs were compared with BM-MSCs, patterns of expression
suggestive of BMP/SMAD signaling in BM-MSCs were observed (Table 2.2). At Day 7,
BMP1, BMP2, and BMP6 were upregulated while only BMP4 was downregulated. At
Day 21, however, only BMP2 was upregulated and BMP4 was downregulated.
Additionally, all BMPRs and SMAD genes demonstrated robust upregulation at both
time points. Results further support that similar to AD-MSCs, osteogenesis of BM-MSCs
is also mediated by BMP/SMAD signaling, and potentially occurs at a time point earlier
than day 21.
TGFβ family members are involved in osteogenesis
In addition to the BMPs, growth factors including EGF, FGF, IGF and their
corresponding receptors are also involved in bone tissue healing, regeneration, and cell
differentiation. In this study we examined 10 growth factors and 6 growth factor
receptors (Table 2.1). In AD-MSCs, IGF1, TGFB2, TGFB3, and TNF were upregulated
while EGF, FGF1, FGF2, and GDF10 were downregulated. All growth factor receptor
genes, including EGFR, IGF1R, TGFBR1, and TGFBR2 were upregulated.
Comparatively, in BM-MSCs, IGF2, TGFB2, and TGFB3 were upregulated while FGF1,
FGF2, IGF1, TGFB1 were downregulated. Correspondingly, the growth factor receptors
including, FGFR2, TGFBR1, and TGFBR2 were upregulated, while only IGF1R was
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downregulated. Fold expression changes between the two cell types were very striking.
At day 7, only GDF10 was downregulated, while at Day 21 both GDF10 and TGFB3
were downregulated (Table 2.2). All other growth factors including EGF, FGF1, FGF2,
IGF1, IGF2, TGFB1, and TGFB2 were upregulated at both time points with significantly
higher changes in TGFB2. Similarly, all growth factor receptors were upregulated at
both time points with the exception of TGFBR2 and EGFR which was downregulated at
day 21 only, suggesting the potential involvement of the TGF beta family of genes and
their corresponding receptors, mediated osteogenesis of MSCs on LOG.
Significant upregulation of angiogenic factors at all-time points
Angiogenesis is closely entwined with osteoblast differentiation. Formation of new
blood vessels along with maintenance of new and old blood vessels are both coupled
with osteogenesis [28]. In AD-MSCs, PDGFA, VEGFA, and VEGFB were all
upregulated (Table 2.1). Comparatively, in BM-MSCs, only VEGFB was upregulated.
There was no downregulation of any angiogenic markers at any time point (Table 2.2).
Interestingly, when AD-MSCs were compared to BM-MSCs, PDGFA, VEGFA and
VEGFB, all displayed significant upregulation at both time points, suggesting the
angiogenic potential of MSCs in presence of LOG.
Cytoscape analysis demonstrates potential gene interactions at the protein level
The significant changes described above were translated to potential signaling
pathways that the MSCs undergo during osteogenesis on LOG. Using Cytoscape, an
open source software platform, we visualized the molecular interaction between the
gene targets and their potential proteins (Figure 2.6). The propellor plots shown in this
figure demonstrate a significantly high number of gene/protein targets from the ECM
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markers and the TGFβ/BMP/SMAD pathways to have a role in osteogenic differentiation
of MSCs on LOG. The plots confirm our earlier report that ECM proteins play an
important role in the adhesion and subsequent differentiation of MSCs on LOG [11].
Data presented here demonstrates that osteogenesis of both the AD and BM MSCs is
potentially mediated by the TGFβ/BMP/SMAD signaling.
Immunofluorescence confirms cytoskeletal organization and distinct ECM protein
expression of BM-MSCs
Phalloidin F-actin staining illustrates cytoskeletal organization and cell adhesion and
hence, is a powerful tool to show cell attachment onto biomaterials. We have previously
demonstrated cytoskeletal health and integrity of AD-MSCs on LOG [11]. In this study,
we confirmed the cytoskeletal organization of BM-MSCs on LOG (Figure 2.7A) at 24 hr
and 21 days i.e. at the adhesion and differentiation time points. Even though the
cytoskeletal integrity appears to be maintained at both time points, subjectively, cells
appear discretely localized and clustered at the 24 hr time point, supporting our earlier
data that cell attachment to LOG surface is not random. Subsequently, the expression
and localization of fibronectin and collagen 1 evaluated at the same time points confirm
that the two ECM proteins have roles in cell adhesion and differentiation on LOG
surface (Figure 2.7B, C). These data complement our report on the behavior of ADMSCs [11]. Subjective evaluation of fibronectin and collagen at 24 hr and at day 21
suggests higher expression and a relatively more discrete pattern of expression at 24hr.
Even though BM-MSCs express these ECM proteins at day 21, cells are sparse and the
expression is weak, suggesting that cells undergo osteogenesis presumably at a time
point earlier than day 21. The significant down regulation of genes at day 21 as
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described in the above sections complements this observation. A future study that
investigates an osteogenic response and the expression of ECM proteins in BM-MSCs,
between 24 hr and day 21 is needed to confirm this data.

DISCUSSION
In this study, we present data comparing the osteogenic behavior of human adipose and bone marrow – derived MSCs in presence of LOG using in vitro osteogenesis
assays and genetic profiling. To our knowledge, this is the first study to compare
changes in gene expressions when MSCs from two distinct tissue sources undergo
spontaneous (without any chemical induction) osteogenic differentiation in presence of
graphene. Additionally, this is the first study reporting simultaneous genetic profiling of a
panel of genes involved in cell adhesion, production of ECM, osteoblast differentiation,
and ossification. Changes in gene expression provides a mechanistic overview of the
key targets that are potentially involved in graphene – mediated osteogenic signaling of
MSCs. This data strengthens the use of MSCs + graphene surfaces as scaffold
components for bone tissue engineering.
When placed in an osteogenic environment, MSCs have the potential to differentiate
into osteoblasts (bone cells). This commitment is regulated by osteoblast-associated
transcription factors (DLX5, RUNX2, SP7, SOX9), adhesion molecules (integrins
β1/ITGB1), and extracellular matrix proteins (ECM) (fibronectin, collagen I) [29]. During
differentiation, cells generate tissue - specific ECM, express ALPL, BGLAP, and SPP1,
and undergo bone cell development. Renowned osteogenic pathways include the
WNT/β-catenin and bone morphogenetic protein (BMP)/transforming growth factor beta
(TGFβ) pathways. The WNT proteins activate at least three distinct intracellular
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signaling cascades important for osteogenic differentiation [30]. Some studies suggest
cross talk between WNT, MAPK, and TGFβ signaling when MSCs undergo
osteogenesis [31]. On the other hand, BMP/TGFβ signaling has been thoroughly
reviewed in bone development which functions through both canonical (SMAD
dependent) and non-canonical (SMAD independent) pathways, thereby mediating
transcription [32, 33]. Additionally, the Hedgehog (Hh) and Notch pathways are
suggested to affect cell osteogenesis, but their exact role is unknown [34-38]. It is thus
evident that the osteogenic signaling pathways are complex and involve a coordinated
action of multiple genes and their corresponding protein factors.
Bone marrow and adipose tissue are the most common MSC resources [39-44].
Although bone marrow is considered the richest source of MSCs in humans and
animals, fat-derived MSCs are preferred in many clinics or in basic research projects,
because the tissue harvest is relatively easy, less invasive, and not associated with
patient morbidity [45-48]. Although MSCs isolated from the two tissue sources adhere to
tissue culture polystyrene surface, show similar expression patterns of cluster-ofdifferentiation markers, morphology, and trilineage differentiation potential in vitro [43],
they might exhibit differences in their lineage-specific features and overall functionality.
These variations have been reported in presence and absence of biomaterials [49-51].
For instance, we expect the BM-MSCs to exhibit an increased potential towards
osteogenesis as studies show that in the absence of any biomaterial, AD and BM-MSCs
undergo osteogenesis by different signaling pathways [52]. Therefore, it is possible that
their interaction with materials might affect this process, and BM-MSCs may not be the
optimal cell type to use. For example, it was found that osteogenic induction of BM-
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MSCs was mediated by the p38 MAPK pathway, while AD-MSCS involved the p44/42
MAPK pathway [25]. Contrary to this report, other studies have found that PDGF
enhances osteogenesis of AD-MSCs, but not BM-MSCs [53]. Hence, for an efficacious
stem cell therapy, it is important to study a specific cell type in context of a given
biomaterial in vitro and in vivo.
The AD and BM-MSCs undergo osteogenesis on tissue culture polystyrene surface
within 21-28 days in conditions of chemical induction. Osteogenesis is a programmed
process which is accompanied by dynamic changes in the expression profiles of
osteoblast-related genes. Early markers of osteogenesis are expressed as early as 710 days post induction [43] [54, 55], and completed within 21-28 days concomitant with
the expression of late osteogenic markers. As a result, we examined differences in gene
expressions at days 7 and 21 when AD and BM-MSCs are cultured on graphene. Since
osteoblast development from MSCs is recognized by mineralization, which can be
visualized by alizarin red staining and quantitated by elution of the red color, we found
that both AD and BM-MSCs were differentiated by 21 days when chemically induced on
tissue culture polystyrene and when non-chemically induced on graphene (Figure 2.2).
Osteogenic differentiation under these media conditions was confirmed by the increase
in ALPL and BGLAP expression in AD-MSCs cultured on graphene relative to the tissue
culture polystyrene surface (Figure 2.4). Lower mineralization was observed when AD
and BM-MSCs were simultaneously exposed to osteo-chemical inducers and graphene.
Although we confirmed the cells were viable (data not shown), it is possible that the
combination triggers distinct signal transduction pathway(s) [26], which is beyond the
scope of this study.
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Graphene-based nanomaterials have been recognized as successful components of
bone tissue engineering scaffolds [4, 56-60]. Studies recognize graphene as a delivery
vehicle to control the release and dosing of potent BMP2 treatments for endogenous
stem cell activation [61-64], or as a nanomaterial which by virtue of its physicochemical
properties creates an osteogenic environment triggering both the endogenous and
exogenous stem cells to undergo osteogenesis. Graphene studies consistently show
osteogenesis of various MSCs sources [17-19, 65-78], which is generally supported by
mineralization stains and upregulation of bone – specific markers i.e. RUNX2, ALPL,
BMP2, BGLAP, SPP1, and COL I. These studies demonstrate the end result of
osteogenic differentiation but lack understanding of how the signaling process occurs.
Most recently, it was shown that human dental pulp MSCs in the presence of graphene
achieved osteogenesis via the integrin/focal adhesion kinase axis, thereby signaling
SMAD phosphorylation, RUNX2 transcription, and production of BGLAP and SPP1
proteins [76]. It is suggested that the carbon arrangement of graphene and its
derivatives mimics an organic bone ECM microenvironment, whereby stem cells can
attach, proliferate and ultimately differentiate under the appropriate cues [11]. As a
result, cell adhesion is the initiating event, since without this attachment, cells have a
limited opportunity to produce their ECM and be signaled into differentiation.
Subsequently, extracellular ligands can bind to cell surface receptors and relay signals
into the nucleus for transcriptional activation that commits osteogenic differentiation. It is
possible that by virtue of its planar structure, the low oxygen content form of graphene
makes cells accessible to the graphene surface, potentially providing guidance and an
appropriate topography to attach, cluster, and thereby differentiate into osteogenic
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lineage. Our data supports this theory as both MSC sources on the low oxygen
graphene either maintained or positively expressed several adhesion (i.e. CDH11,
ICAM1, ITGA1, ITGA3, VCAM1) and ECM (i.e. BGN, COL1A1, COL3A1, COL10A1,
COL14A1, COL15A1, FN1) genes over time.
In addition to osteogenesis, there are some reports demonstrating the angiogenic effect
of graphene nanomaterials. Park et al. showed that rGO flakes incorporated with MSC
spheroids stimulated the expression of angiogenic growth factors, including VEGF,
HGF, and FGF2 [79]. Similarly, it was found that graphene-based biomaterials not only
differentiated cells into osteoblasts, but simultaneously increased other angiogenic
markers, namely von Willibrand factor (vWF) and angiopoietin-1 (ang-1) [74]. Other
studies have found that low concentrations of graphene derivatives (up to 100 ng/mL -1)
triggers a pro-angiogenic environment via Akt and nitric oxide signaling of endothelial
cells [80].
Our data supports a recent study that demonstrated graphene – mediated osteogenesis
via BMP/SMAD pathways [81]. However, for the first time, we provide information on the
various protein isoforms belonging to these families. We not only show expressions of
osteoblast-related genes, but also the coordinated involvement of cellular adhesion
molecules, ECM, growth factors, and angiogenic factors which are all necessary for
osteogenic signaling, maintenance, and survival. Additionally, no study has completed a
head-to-head comparison of different MSC sources on graphene. The current literature
primarily studies MSCs associated with mineralized tissues (i.e., bone marrow, dental
pulp, and periodontal ligament) [18, 19, 70, 71, 73, 74, 76-78], with only one other
research group identifying osteogenesis of AD-MSCs on graphene [69]. Our study
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recognizes that AD-MSCs may achieve osteogenesis slower than BM-MSCs but are still
a valid and feasible resource for bone healing and repair.
In this study, we demonstrate that both AD and BM-MSCs undergo osteogenesis on
graphene surfaces which is mediated by multiple transcription factors in addition to
RUNX2, the most commonly reported in all the studies described above. The
transcriptional regulation appears to be controlled by RUNX2 and DLX5. This is a novel
finding and suggests that the action of RUNX2 and DLX5 may be synergistic in the
osteogenic behavior of BM-MSCs in presence of graphene. DLX5 and RUNX2 has
been reported to have a significant role in early bone development, by mediating
intramembranous and endochondral ossification, respectively [82-84]. Additionally,
comparative assessment indicates that the osteogenic commitment of BM-MSCs occurs
at a time point earlier than day 21. This is significant and can greatly affect in vitro and
in vivo studies using graphene nanomaterials. Other novel targets identified in this study
include PHEX (phosphate‑regulating gene with homologies to endopeptidase on the X
chromosome), an osteoblast-related gene that when inactive, leads to excessive
phosphate wasting and consequently causes rickets [85]. In contrast to bone, we also
examined chondrocyte-related genes, namely SOX9 and COMP (cartilage oligomeric
matrix protein, data not shown) which were downregulated in both cell types over time.
Finally, our data supports that culturing MSCs on graphene upregulates angiogenic
markers, VEGF and PDGF. Interestingly, PDGF bridges the osteogenic and angiogenic
pathways by freeing MSCs from blood vessels and positively regulating VEGF signaling
[86]. This data suggests that graphene surfaces could simultaneously attract blood
vessel ingrowth when implanted in vivo.
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CONCLUSION
This study investigates the genetic responses when MSCs undergo osteogenesis on
graphene. Graphene genetically supports osteogenesis of MSCs by multiple
transcription factors, extracellular matrix production, adhesion molecules, growth factor
signaling, and angiogenic markers. Additionally, we provide this information from
various MSCs sources, which have similar outcomes on graphene, but different
mechanisms to osteoblast-development. These results provide optimism that
exogenous MSCs implanted with graphene materials could support new bone
development in future animal models and human clinical trials.
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APPENDIX

Figure 2.1. Atomic force microscopy. (Left panel) plot of roughness values (Rq and Ra) from 7
AFM imaged: data shown with diamonds, mean value with solid circle + line, and the standard
deviation with whiskers. (Right panel) representative AFM image (approximately the average Rq and
Ra values from around spot surface on 100 mm plastic petri dish.
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Figure 2.2. Osteogenic differentiation assay. AD-MSCs or BM-MSCs were seeded on tissue
culture polystyrene (control) or LOG and cultured in either undifferentiated media (without
osteogenic induction) or differentiated media (with osteogenic induction) for 21 days. Cells were
then exposed to Alizarin red staining and read at absorbance 570 nm for calcium quantitation.
Statistical significance (p<0.05) is indicated by asterisks.
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Figure 2.3. Assessment of RNA Quality. (A) Electrophoresis of total RNA from AD-MSCs
cultured on LOG for either 7 or 21 days. (B) Electrophoresis of total RNA from BM-MSCs
cultured on LOG for either 7 or 21 days. Arrows indicate bands of ribosomal subunits. (C)
Electropherogram of AD-MSCs cultured on LOG for either 7 days (RIN = 9.10) or (D) 21 days
(RIN = 9.60). (E) Electropherogram of BM-MSCs cultured on LOG for either 7 days (RIN =
9.40) or (F) 21 days (RIN = 9.50).
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Figure 2.4. The effects of LOG on RUNX2, BGLAP, and ALPL gene expressions. AD-MSCs were
cultured for 21 days in either an osteogenic differentiation media on tissue culture polystyrene (control) or in
undifferentiated media on low oxygen graphene (LOG). Data was normalized to 1 by B2M. n =3; * indicates
p < 0.05. Error bars presented as standard deviation.
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Figure 2.5. Differentially expressed genes when AD-MSCs and BM-MSCs undergo
osteogenesis on LOG. (A) Percentage of significantly changed genes at Day 21 in
comparison to its control at Day 7. (B) Percentage of significantly changed genes in BMMSCs at each time point in comparison to AD-MSCs set as the control.

70

Figure 2.6. Propeller plots depicting potential gene targets and corresponding protein
interactions. Cytoscape analyses illustrating differentially expressed genes related to Osteoblast
and Angiogenic factors (A), Cellular adhesion and transcriptional regulation (B), and Growth
factors, ECM markers and members of BMP/SMAD signaling (C) to be the key targets involved in
osteogenic differentiation of human AD and BM – derived MSCs. In all analyses, day 7 expression
was set as control and day 21 was the treated group. The cell types are color coded, with ADMSCs (Blue) and BM-MSCs (Red), and the plot arcs with increasing significance moving
clockwise and a decrease is represented as anticlockwise. (D) Connectively plot for target genes
sorted based on established functional groups. Lines linking nodes indicate relationships between
associated proteins as annotated by STRING application software within the Cytoscape platform.
Interconnective links within and between functional groupings can be observed.
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Figure 2.7. Immunofluorescence assays. Assays were performed to assess
cytoskeletal organization of BM-MSCs using F-actin (A) and expression of specific ECM
proteins (B, C) during cell adhesion at 24 hr and differentiation at day 21.
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Table 2.1. Gene expressions of AD-MSCs and BM-MSCs cultured on LOG between 7 and 21 days.
CT values for each gene were normalized using a housekeeping gene and then the fold changes were
calculated by using Day 7 expression as the control and Day 21 expression as the tested group. NC =
No Change; ND = Non Detectable.

Gene Description

Symbol

Fold
Change
(AD-MSCs)

Fold
Change
(BM-MSCs)

Transcriptional Regulation
Distal-less homeobox 5
Runt-related transcription factor 2
SRY (sex determining region Y)-box 9
Sp7 transcription factor

DLX5
RUNX2
SOX9
SP7

ND
1.57
0.70
0.65

0.26
0.78
0.64
0.21

Osteoblast-Related
Alkaline phosphatase, liver/bone/kidney
Bone gamma-carboxyglutamate (gla) protein/osteocalcin
Phosphate regulating endopeptidase homolog, X-linked
Secreted phosphoprotein 1/osteopontin

ALPL
BGLAP
PHEX
SPP1

2.09
1.30
1.28
0.30

3.43
0.50
1.49
1.86

BGN
COL1A1
COL1A2
COL3A1
COL5A1
COL10A1
COL14A1
COL15A1
FN1

1.36
NC
0.81
1.22
NC
NC
1.31
2.50
1.49

1.46
1.27
NC
NC
NC
2.11
13.33
11.63
2.28

CDH11
ICAM1
ITGA1

NC
4.69
1.62

1.62
6.28
1.21

ITGA2

0.49

0.29

ITGA3

NC

1.66

ITGB1

0.66

0.78

VCAM1

2.42

11.13

Extracellular Matrix Markers
Biglycan
Collagen, type I, alpha 1
Collagen, type I, alpha 2
Collagen, type III, alpha 1
Collagen, type V, alpha 1
Collagen, type X, alpha 1
Collagen, type XIV, alpha 1
Collagen, type XV, alpha 1
Fibronectin 1
Cellular Adhesion
Cadherin 11, type 2, OB-cadherin (osteoblast)
Intercellular adhesion molecule 1
Integrin, alpha 1
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2
receptor)
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
VLA-3 receptor)
Integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12)
Vascular cell adhesion molecular 1
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Table 2.1. Continued.

Symbol

Fold
Change
(AD-MSCs)

Fold
Change
(BM-MSCs)

BMP and SMAD Signaling
Bone morphogenetic protein 1
Bone morphogenetic protein 2
Bone morphogenetic protein 4
Bone morphogenetic protein 6
Activin A receptor, type I
Bone morphogenetic protein receptor, type IA
Bone morphogenetic protein receptor, type IB
Bone morphogenetic protein receptor, type II
SMAD family member 1
SMAD family member 2
SMAD family member 3
SMAD family member 4
SMAD family member 5

BMP1
BMP2
BMP4
BMP6
ACVR1
BMPR1A
BMPR1B
BMPR2
SMAD1
SMAD2
SMAD3
SMAD4
SMAD5

NC
NC
1.94
0.15
NC
NC
NC
1.19
NC
1.24
2.62
NC
1.14

NC
0.25
2.61
0.05
NC
1.18
2.04
0.63
0.61
NC
2.13
0.93
0.88

Growth Factors
Epidermal growth factor
Epidermal growth factor receptor
Fibroblast growth factor 1 (acidic)
Fibroblast growth factor 2 (basic)
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Growth differentiation factor 10
Insulin-like growth factor 1 (somatomedin C)
Insulin-like growth factor 2 (somatomedin A)
Insulin-like growth factor 1 receptor
Transforming growth factor, beta 1
Transforming growth factor, beta 2
Transforming growth factor, beta 3
Transforming growth factor, beta receptor 1
Transforming growth factor, beta receptor II (70/80kDa)
Tumor necrosis factor

EGF
EGFR
FGF1
FGF2
FGFR1
FGFR2
GDF10
IGF1
IGF2
IGF1R
TGFB1
TGFB2
TGFB3
TGFBR1
TGFBR2
TNF

0.55
1.99
0.74
0.50
NC
NC
0.18
2.53
NC
1.44
NC
1.52
2.06
1.32
1.57
1.76

NC
NC
0.69
0.78
NC
2.65
ND
0.66
2.40
0.76
0.76
1.53
1.80
1.99
2.60
ND

FLT1

NC

ND

PDGFA
VEGFA
VEGFB

1.34
1.40
1.38

NC
NC
1.40

Gene Description

Angiogenic Factors
Fms-related tyrosine kinase 1 (vascular endothelial
growth factor/vascular permeability factor receptor)
Platelet-derived growth factor alpha polypeptide
Vascular endothelial growth factor A
Vascular endothelial growth factor B
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Table 2.2. Gene expressions of BM-MSCs in comparison to AD-MSCs cultured on LOG for either 7 or
21 days. CT values for each gene were normalized using a housekeeping gene and then the fold
changes were calculated by using AD-MSCs as the control and BM-MSCs as the tested group.NC =
No Change; ND = Non Detectable.
Day 7

Day 21

Gene Description

Symbol

Fold
Change

Fold
Change

Transcriptional Regulation
Distal-less homeobox 5
Runt-related transcription factor 2
SRY (sex determining region Y)-box 9
Sp7 transcription factor

DLX5
RUNX2
SOX9
SP7

60.69
7.24
6.85
9.56

11.24
2.24
3.89
1.87

Osteoblast-Related
Alkaline phosphatase, liver/bone/kidney
Bone gamma-carboxyglutamate (gla) protein/osteocalcin
Phosphate regulating endopeptidase homolog, X-linked
Secreted phosphoprotein 1/osteopontin

ALPL
BGLAP
PHEX
SPP1

0.01
3.69
0.45
NC

0.01
0.88
0.33
3.06

BGN
COL1A1
COL1A2
COL3A1
COL5A1
COL10A1
COL14A1
COL15A1
FN1

1.93
NC
NC
0.45
2.08
13.21
4.01
0.08
2.73

1.29
0.59
NC
0.31
NC
12.50
25.34
0.22
2.58

CDH11
ICAM1
ITGA1

2.11
0.51
2.00

2.2
0.43
NC

ITGA2

1.95

0.71

ITGA3

5.00

4.34

ITGB1

1.54

1.14

VCAM1

482.15

1376.38

Extracellular Matrix Markers
Biglycan
Collagen, type I, alpha 1
Collagen, type I, alpha 2
Collagen, type III, alpha 1
Collagen, type V, alpha 1
Collagen, type X, alpha 1
Collagen, type XIV, alpha 1
Collagen, type XV, alpha 1
Fibronectin 1
Cellular Adhesion
Cadherin 11, type 2, OB-cadherin (osteoblast)
Intercellular adhesion molecule 1
Integrin, alpha 1
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2
receptor)
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
VLA-3 receptor)
Integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29 includes MDF2, MSK12)
Vascular cell adhesion molecule 1
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Table 2.2. Continued.
Day 7

Day 21

Symbol

Fold
Change

Fold
Change

BMP and SMAD Signaling
Bone morphogenetic protein 1
Bone morphogenetic protein 2
Bone morphogenetic protein 4
Bone morphogenetic protein 6
Activin A receptor, type I
Bone morphogenetic protein receptor, type IA
Bone morphogenetic protein receptor, type IB
Bone morphogenetic protein receptor, type II
SMAD family member 1
SMAD family member 2
SMAD family member 3
SMAD family member 4
SMAD family member 5

BMP1
BMP2
BMP4
BMP6
ACVR1
BMPR1A
BMPR1B
BMPR2
SMAD1
SMAD2
SMAD3
SMAD4
SMAD5

1.94
17.92
0.16
4.05
2.26
2.23
NC
4.53
4.14
2.30
NC
1.96
3.15

NC
3.36
0.13
NC
1.61
1.72
NC
1.50
1.58
1.29
NC
1.06
1.50

Growth Factors
Epidermal growth factor
Epidermal growth factor receptor
Fibroblast growth factor 1 (acidic)
Fibroblast growth factor 2 (basic)
Fibroblast growth factor receptor 1 (acidic)
Fibroblast growth factor receptor 2 (basic)
Growth differentiation factor 10
Insulin-like growth factor 1 (somatomedin C)
Insulin-like growth factor 2 (somatomedin A)
Insulin-like growth factor 1 receptor
Transforming growth factor, beta 1
Transforming growth factor, beta 2
Transforming growth factor, beta 3
Transforming growth factor, beta receptor 1
Transforming growth factor, beta receptor II (70/80kDa)
Tumor necrosis factor

EGF
EGFR
FGF1
FGF2
FGFR1
FGFR2
GDF10
IGF1
IGF2
IGF1R
TGFB1
TGFB2
TGFB3
TGFBR1
TGFBR2
TNF

4.78
2.38
3.44
1.53
2.37
7.57
0.02
7.34
34.30
5.72
2.30
51.51
NC
4.07
0.64
ND

7.73
0.61
1.99
1.47
NC
16.8
0.10
1.20
43.71
1.89
NC
32.22
0.71
3.80
0.66
NC

FLT1

NC

NC

PDGFA
VEGFA
VEGFB

3.07
4.07
1.65

1.44
1.88
NC

Gene Description

Angiogenic Factors
Fms-related tyrosine kinase 1 (vascular endothelial
growth factor/vascular permeability factor receptor)
Platelet-derived growth factor alpha polypeptide
Vascular endothelial growth factor A
Vascular endothelial growth factor B
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CHAPTER III:
COMPARING OSTEOGENIC GENE EXPRESSION OF HUMAN MSCS
ON RGO AND GO SUBSTRATES
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ABSTRACT
Treatment of traumatic bone injuries is increasingly relying on novel materials that not
only supports a defect, but also invokes stem cells into functional bone tissue.
Graphene, a carbon-based biomaterial, spontaneously supports new bone
differentiation of adult, mesenchymal stem cells (MSCs) without any osteo-chemical
inducers. The two most common graphene derivatives for bone differentiation is
graphene oxide (GO) and reduced graphene oxide (rGO). However, the question arises
if one signals MSC bone differentiation differently than another. To answer this
question, we examined the genetic regulation of MSCs cultured on GO and rGO
substrates, including genes related to transcriptional regulation, osteoblast-related, the
ECM, cell adhesion, growth factors, BMP & SMAD signaling, angiogenic factors, and
MMPs. We found that both GO and rGO substrates supported osteogenic gene
expression of MSCs. However, a head-to-head comparison showed that genes
important to the osteoblast differentiation process were robustly upregulated on rGO
than GO. Overall, the information gained from this study could elucidate the optimal
graphene derivative for bone differentiation of future in vivo and clinical studies.
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INTRODUCTION
Treatment of traumatic bone injuries is increasingly relying on novel materials that not
only supports a defect, but also invokes stem cells into functional bone tissue. Ideal
bone biomaterials are still under investigation, but graphene materials are at the
forefront as the next clinical standard. Graphene, a carbon-based monolayer of
graphite, is exceedingly strong, light, and yet very flexible, making it an attractive
material that provides both skeletal support and endures mechanical stress. Better yet,
graphene is a delivery vehicle for stem cell therapies and growth factors at the bone
injury site [1-4]. Additionally, graphene substrates supports spontaneous bone
differentiation of adult mesenchymal stem cells (MSCs), without any osteo-chemical
inducers [5-7]. This means graphene is unlike other bioinert materials (i.e., metals,
ceramics, etc.) which are incapable of signaling new bone development [8, 9].
Since graphene’s discovery in 2004, various derivatives have been developed to
increase its biocompatibility and hydrophilicity. The major graphene derivatives are
graphene oxide (GO) and reduced graphene oxide (rGO), both of which are
commercially available products, that supports in vitro bone differentiation of stem cells
[10-14]. In bone tissue engineering, MSCs are the preferred stem cell source as these
cells do not demonstrate immunological rejection and are derived from healthy adults,
thereby eliminating the ethical concerns of embryonic stem cells [15-17]. Additionally,
MSCs are multipotent, meaning they can differentiate into a variety of cell lineages,
including osteocytes, chondrocytes, and adipocytes [18]. Therefore, it is important to
focus on biological materials, such as graphene, that mimics a bone microenvironment
and sustains bone differentiation of MSCs.
Previously, we reported that low oxygen graphene (LOG), an analog of rGO, genetically
supported bone differentiation of both human adipose derived MSCs (AD-MSCs) and
human bone marrow derived MSCs (BM-MSCs) [5]. However, since GO and rGO are
the established graphene derivatives, the question arises if one signals MSC bone
differentiation differently than another. To answer this question, we examined the
genetic responses of MSCs cultured in the presence of GO and rGO substrates at
various time points using focused osteogenic PCR arrays. To our knowledge, there are
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no head-to-head comparisons of MSC gene expression exposed to GO and rGO.
Overall, the information gained from this study could elucidate the optimal graphene
derivative for bone differentiation of future in vivo and clinical studies.

METHODS
Preparation of rGO and GO
rGO and GO were commercially purchased from Cheap Tubes Inc. (Grafton, VT) and
dispersed in ethanol/water by sonication for 60 min and 20 min, respectively. Non-tissue
culture dishes were then coated with either rGO or GO at a final concentration of 0.2
mg/cm2.
Cell Culture on rGO and GO
We previously isolated and characterized human AD-MSCs [6, 19] which was approved
by an IRB protocol at the University of Tennessee Medical Center in Knoxville.
The AD-MSCs were first grown to confluency on standard tissue culture polystyrene in
growth media using DMEM-F12, supplemented with 10% FBS, 1% penicillin, and 1%
streptomycin. Cells were incubated in an atmosphere of 5% CO2 at 37°C. For
experimental conditions, the media was removed prior to separating cells with 0.05%
trypsin for ~40 min. The cells were then reseeded at 1 X 106 / 100 mm on rGO or GO
coated dishes and harvested after either 3, 7, 14, or 21 days. Throughout the study,
cells were maintained in growth media without any osteo-differentiation inducers.
RNA Isolation
At each time point, total RNA was isolated using the Qiagen RNeasy kit as previously
described [5]. RNA quantity, purity, and quality were confirmed before proceeding to
PCR analysis.
Human Osteogenesis PCR Array
RT2 Profiler PCR Human Osteogenesis Array (Qiagen, Hilden, Germany, #PAHS-026Z)
was used to evaluate differentially expressed genes of AD-MSCs on GO or rGO, similar
to a recently published report [5]. Briefly, 1 µg of RNA was reversed transcribed for
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cDNA synthesis and PCR reactions were completed according to the manufacturer’s
recommendations [20]. These microplate arrays contain primers that target 84 genes of
interest. Following analysis, genes of interest were classified into one of the following
categories: transcriptional regulation, osteoblast-related, extracellular matrix markers,
cellular adhesion, BMP and SMAD signaling, growth factors, angiogenic factors, and
bone remodeling.
Statistical Analysis
Gene expressions from CT values were uploaded into Qiagen Gene Globe software to
determine the relative fold change (https://geneglobe.qiagen.com/us/analyze/). We first
examined gene expression of AD-MSCs on GO and rGO overtime by designating Day 3
as the control group and subsequent time points as the tested groups. Thereafter, we
then compared gene expression between both graphene derivatives at each time point,
using GO as the control and rGO as the tested group. All comparisons were normalized
using ribosomal protein, large, P0 (RPLP0). Data is shown from triplicate experiments,
with fold changes statistically significant at p<0.05. A statistically significant gene with a
fold change value >1 and <1 indicated upregulation and downregulation, respectively.

RESULTS
Total number of upregulated genes is greater on rGO than GO in MSCs cultured
at early time points
We first investigated gene expression of MSCs cultured on GO or rGO overtime (from
Day 3 up to Day 21).
When AD-MSCs were cultured on GO, gene expression from day 3 to day 7 showed 8
upregulated and 22 downregulated genes. However, the number of significant genes
appeared to increase over extended time periods. Gene expression from day 3 to day
14 showed 24 upregulated and 13 downregulated genes and from day 3 to day 21 there
were 53 upregulated and 4 downregulated genes. Overall, these comparisons
suggested active bone differentiation of MSCs on GO overtime.
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When AD-MSCs were cultured on rGO, gene expression from day 3 to day 7 showed 8
upregulated and 43 downregulated genes, whereas from day 3 to day 14, there were 16
upregulated and 39 downregulated genes.
To further understand the reaction of MSCs between GO and rGO, we investigated
gene expression when GO was set as the control and rGO as the tested group at each
time point. At day 3, we found 33 upregulated and 8 downregulated genes. Similarly, at
day 7, we found 32 upregulated and 13 downregulated genes. By day 14, there were 25
upregulated and 29 downregulated genes. Overall, this data suggested that genetic
activity of MSCs is more robust on rGO at early time points.
Osteoblast Transcription is greater on rGO than GO in MSCs cultured at early
time points
We next evaluated specific gene clusters important to the bone differentiation process,
beginning with genes involved in transcriptional regulation.
When AD-MSCs were cultured on GO, gene expressions from Day 3 to Day 7 showed
downregulation of SOX9, whereas from Day 3 to Day 21, RUNX2 and SP7 were both
upregulated (Table 3.1).
When AD-MSCs were cultured on rGO, gene expressions from Day 3 to Day 7 showed
downregulation of SOX9. Additionally, from Day 3 to Day 14, both SOX9 and SP7 were
downregulated (Table 3.2).
When comparing between GO and rGO, RUNX2 and SOX9 were upregulated at all time
points (Table 3.3).
Overall, this data shows MSCs on GO express upregulated osteoblast transcription
factors, but only after 21 days of culturing. However, when comparing both materials,
expression of osteoblast transcription is greatest on rGO than GO at early time points.
MSCs cultured on GO and rGO express specific osteoblast-related markers
overtime
When AD-MSCs were cultured on GO, gene expressions from day 3 to day 7 showed
downregulation of SPP1. However, upregulation of osteoblast-related genes initiated

82
from day 3 to day 14. From day 3 to day 21, all osteoblast-related genes (ALPL,
BGLAP, PHEX, and SPP1) were upregulated (Table 3.1).
When AD-MSCs were cultured on rGO, gene expressions from day 3 to day 7 showed
downregulation of BGLAP, SPP1, but upregulation of ALPL by nearly 5-fold. The
expression pattern of these genes was consistent from day 3 to day 14 (Table 3.2).
When comparing between GO and rGO, day 3 expression showed ALPL and BGLAP
were downregulated and upregulated, respectively, whereas at day 7, ALPL was
upregulated. However, by day 14, ALPL, BGLAP, and SPP1 were all downregulated
(Table 3.3).
Overall, this data suggests that specific osteoblast-related genes occurs within 14 days
of MSCs cultured on GO, whereas on rGO expression occurs within 7 days.
MSCs cultured on rGO express more upregulated extracellular matrix markers
than GO overtime
When AD-MSCs were cultured on GO, most ECM genes from day 3 to day 7 were
downregulated (BGN, COL1A1, COL3A1, COL5A1, COL15A1, and FN1); only
COL14A1 was upregulated. This pattern was nearly consistent from day 3 to day 14.
However, gene expression between day 3 to day 21 showed no downregulated genes
and robust upregulation of COL10A1 (~9 fold) and COL14A1 (~10.5 fold) (Table 3.1).
When AD-MSCs were cultured on rGO, gene expressions from day 3 to day 7 showed
downregulation of BGN, COL15A1, and FN1, but upregulation of COL1A1, COL1A2,
COL3A1, and COL14A1. Similarly, expression of these genes was consistent from day
3 to day 14, with the exception of upregulated BGN and no change of COL15A1
expression (Table 3.2).
When comparing between GO and rGO, day 3 expression showed all significant genes
were downregulated (BGN, COL1A1, COL1A2, and COL15A1), whereas at day 7, all
significant genes were upregulated (BGN, COL3A1, COL5A1, and FN1). By day 14,
COL1A1, COL3A1, COL5A1, and COL15A1 were all upregulated, while BGN and
COL14A1 were downregulated (Table 3.3).
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Overall, this data shows that MSCs cultured on rGO express several upregulated ECM
genes at early and later time points.
Cellular Adhesion is greater on rGO than GO in MSCs cultured at early time
points
When AD-MSCs were cultured on GO, gene expressions from day 3 to day 7 showed
nearly all genes were downregulated (ITGA1, ITGA2, ITGA3, and ITGB1) except for
upregulated ICAM1 expression. From day 3 to day 14, only ITGA2 was downregulated,
while ICAM1 and VCAM 1 were upregulated. However, gene expressions from day 3 to
day 21 showed all significant genes were upregulated (CDH11, ICAM1, ITGA1, and
ITGA3) (Table 3.1).
When AD-MSCs were cultured on rGO, gene expressions from day 3 to day 7 showed
all significant genes were downregulated (CDH11, ICAM1, ITGA1, ITGA2, and ITGA3),
with the exception of upregulated VCAM1 expression. Similarly, expression of these
genes were consistent from day 3 to day 14, with the exception of downregulated
ITGB1 (Table 3.2).
When comparing between GO and rGO, day 3 expression showed upregulated ICAM1,
ITGA1, and ITGA2, but downregulated VCAM1. At day 7, ITGA1, ITGA2, ITGA3, and
ITGB1 were upregulated, but VCAM1 was downregulated. By day 14, ITGA2 and
ITGB1 were upregulated, while CDH11, ITGA3, and VCAM1 were downregulated
(Table 3.3).
Overall, this data suggests MSCs on GO express upregulated adhesion factors
primarily after 21 days of culturing. However, when comparing both materials,
expression of adhesion-related genes were greater on rGO than GO at early time
points.
BMP & SMAD signaling is greater on rGO than GO in MSCs cultured at early time
points
When AD-MSCs were cultured on GO, expressions from day 3 to day 7 showed
downregulation of BMP1 and BMP6. From day 3 to day 14, BMP2, BMP4, and
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BMPR1B were upregulated. However, expression from day 3 to day 21 showed
upregulation of nearly all BMP and SMAD genes (BMP2, BMP4, ACVR1, BMPR1A,
BMPR1B, BMPR2, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5); only BMP6 was
downregulated (Table 3.1).
When AD-MSCs were cultured on rGO, gene expressions from day 3 to day 7 and day
3 to day 14, showed nearly all BMP and SMAD genes were downregulated (Table 3.2).
When comparing between GO and rGO, day 3 and day 7 expression showed nearly all
BMP and SMAD genes were upregulated. Interestingly, BMP2 was robustly expressed
at day 3 (~48 fold), compared to day 7 (only ~6 fold). As BMP2 potently stimulates bone
differentiation at low concentrations, this suggests that MSC differentiation is rapid on
rGO in comparison to GO. We also observed other BMP genes appeared to have
greater expression at day 3 than at day 7 such as BMP6 (~10 fold and ~4 fold,
respectively) and BMPR1B (~5 fold and ~3 fold, respectively). However, by day 14 there
were fewer upregulated genes, and for the first time expressed downregulation of
BMP4, SMAD2, and SMAD4 (Table 3.3).
Overall, this data suggests MSCs on GO express upregulation of both BMP and SMAD
signaling factors, but mainly after 21 days of culturing. However, when comparing both
materials, expression of these genes were greater on rGO than GO at early time points.
Growth factor signaling is greater on rGO than GO in MSCs cultured at early time
points
When AD-MSCs were cultured on GO, expressions from day 3 to day 7 showed all
significant genes were downregulated (FGF1, FGF2, FGFR2, GDF10, and TGFB1).
This pattern was nearly consistent from day 3 to day 14, but additionally showed
upregulated EGFR, IGF1, TGFBR2, and TNF. However, expressions from day 3 to day
21 showed only downregulation of GDF10 and several upregulated genes (EGF, EGFR,
FGFR1, IGF1, IGF2, IGF1R, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, and TNF)
(Table 3.1).
When AD-MSCs were cultured on rGO, expressions from day 3 to day 7 showed only
upregulation of EGF, whereas all other significant genes were downregulated (EGFR,
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FGF1, FGFR1, GDF10, IGF1, IGF1R, TGFB1, TGFB3, and TGBR1). A similar pattern
was observed from day 3 to day 14, however, IGF1 and TGFB2 were upregulated
(Table 3.2).
When comparing between GO and rGO, most genes were upregulated at day 3 (EGFR,
FGFR1, IGF1, IGF2, IGF1R, TGFB1, TGFB3, TGFBR1, and TGFBR2), with
downregulation of FGFR2 and GDF10 (Table 3.3). Similarly, all significant genes were
upregulated at day 7, with FGF2 upregulated by ~20 fold. However, expression at day
14 showed the most downregulated genes (EGFR, FGFR2, GDF10, TGFBR2, and
TNF), but also maintained upregulation of several other growth factors.
Overall, this data suggests MSCs on GO express upregulation of several growth
factors, but mainly after 21 days of culturing. However, when comparing both materials,
expression of these genes were greater on rGO than GO at early time points.
rGO and GO supports expression of angiogenic factors in MSCs
When AD-MSCs were cultured on GO, gene expressions from day 3 to day 7 had no
change, while from day 3 to day 14 only VEGFB was upregulated. However, gene
expressions from day 3 to day 21 showed upregulation of both VEGFA and VEGFB
(Table 3.1).
When AD-MSCs were cultured on rGO, genes expressions from day 3 to day 7 showed
all genes were downregulated (FLT1, PDGFA, VEGFA, and VEGFB). Similarly,
expression of these genes were consistent from day 3 to day 14, except for FLT1 which
had no change (Table 3.2).
When comparing between GO and rGO, day 3 expression showed upregulation of
PDGFA. However, day 7 expression showed downregulation of FLT1 and VEGFB. By
day 14, FLT1 and PDGFA were upregulated, while VEGFA and VEGFB were
downregulated (Table 3.3).
Overall, this data suggests that MSCs cultured on GO and rGO can secrete bioactive
factors that attracts new blood vessel ingrowth, which is critical to sustaining newly
developed bone in vivo.
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MMP signaling is greater on rGO than GO in MSCs cultured at early time points
When AD-MSCs were cultured on GO, gene expressions from day 3 to day 7 showed
upregulation of MMP2 and MMP10 (Table 3.1). Interestingly, from day 3 to day 14 and
from day 3 to day 21, all bone remodeling genes tested (MMP2, MMP8, MMP9, and
MMP10) were upregulated, with robust expression of MMP8 (~12 and 19-fold,
respectively).
When AD-MSCs were cultured on rGO, gene expressions from day 3 to day 7 showed
downregulation of MMP2 and MMP10 (Table 3.2). However, day 3 to day 14 showed
upregulation of MMP8 and MMP9.
When comparing between GO and rGO, nearly all MMPs tested were upregulated at all
time points (Table 3.3). Interestingly, robust expression of MMP10 was observed at day
3 (~33 fold), but only ~2 fold at day 7 and day 14. Similarly, MMP2 and MMP8 were
robustly expressed at day 3 than at day 7 or day 14.
Overall, MSCs cultured on GO and rGO express several MMPs, which are important to
bone remodeling. Additionally, comparison of GO and rGO reveals MMP expression is
notably rapid on rGO.

DISCUSSION
The treatment of traumatic bone injuries is actively investigating biocompatible materials
that promotes bone differentiation of stem cells and osteoprogenitors. Graphene, a
carbon-based layer of graphite, has very strong and flexible characteristics that mimics
natural bone [21]. Simultaneously graphene materials support stem cell bone
differentiation, thereby making it an attractive bone substitute [22, 23].
The two most commonly used graphene sources are GO and rGO, with the biggest
difference being the amount of oxygen content. Pristine graphene is commonly oxidized
with oxygen-containing functional groups (i.e., hydroxyl, epoxy, and carboxyl) to
increase biocompatibility and hydrophilicity [24]. The oxidation of pristine graphene
produces GO, typically having a C:O ratio of 3:1 (~33% oxygen content) [25]. However,
the introduction of functional oxygen groups tampers the natural conductivity of pristine
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graphene [26]. As a result, the development of rGO, having a C:O ratio of 13:1 (~13%
oxygen content), partially eliminates the functional oxygen groups and restores
electrical conductivity potential [27]. In laymen’s terms, rGO is thought as the “happy
medium” between pristine graphene and GO.
There are few studies that have compared cell activity between GO and rGO. Jaworski
et al., 2015 evaluated the toxicity of GO and rGO on human glioblastoma cells and
found that both treatments reduced cell viability and proliferation with increasing doses,
but yet rGO was more toxic than GO [28]. Other studies indicate that the method of
producing rGO strongly influences cell viability and cytotoxicity [29-31]. For example,
Jagielllo et al., 2019 found that human umbilical cord MSCs (hUC-MSCs) cultured on
GO and a lowly-reduced rGO substrate (via ascorbic acid) had similar cell viability and
proliferation rates, which was comparable to control cells cultured on polystyrene [30].
However, hUC-MSCs exposed to a highly reduced rGO substrate (via sodium
hypophosphite) demonstrated reduced proliferation and an increase in cell death. It is
believed that rGO cytotoxicity is due to greater intracellular reactive oxygen species,
thus contributing to DNA damage, cell cycle arrest, and ultimately cell death [29, 32].
Therefore, the method of producing rGO should be seriously considered for an optimal
cell environment in tissue engineering.
There are several studies and reviews that have established GO and rGO as bone
scaffolds, but most studies have examined these materials individually [12, 33-35]. In
this study, we sought to complete a head-to-head comparison of genes important to
MSC bone differentiation between GO and rGO over 21 days. These genes were
categorized as either transcriptional regulation, osteoblast-related, ECM, cell adhesion,
BMP & SMAD signaling, growth factors, angiogenic factors, or bone remodeling. These
clusters are well established in the bone differentiation process and have been similarly
reported [5, 36-42]. Throughout this study, we observed three main trends: (1) Several
genes important to bone development were gradually upregulated when MSCs were
cultured on GO after 21 days of culturing (2) gene expression on rGO overtime were
mainly downregulated, but (3) upregulated gene expression was greatest on rGO in
comparison to GO at early time points. More specifically, the latter comparison
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observed that osteoblast transcription, cellular adhesion, BMP & SMAD signaling,
several growth factors, and MMP expression were greater on rGO than GO. This
suggests that bone differentiation occurs earlier on rGO in comparison to GO. For
example, we were surprised to find that BMP2 (the dominant growth factor for bone
development), was upregulated by ~48 fold on rGO in comparison to GO, after just 3
days of culturing. This could partially explain why most genes were downregulated on
rGO overtime; if cells have completed the bone differentiation process, then they
become inactive quiescent bone cells [43]. Interestingly, we could not retrieve cells from
rGO at day 21 using 0.05% trypsin (n = 2). We did obtain cells using 0.25% tryspin,
however it would not be fair to include this analysis as excessive trypsinization can alter
the gene expression profile [44]. Additionally, the current analysis revealed that cell
adhesion factors on rGO are stronger than the same cells exposed to GO. Therefore, it
is not surprising that cells on rGO imposed challenges for detaching with a lower
concentration of trypsin. A few other limitations from this study are that we did not
compare mineralization content or surface topography. However, we expect that data
will be completed for a future publication.
It is unclear why there are different gene expression profiles between GO and rGO.
However, it should be noted that rGO has a much larger surface area (~2400 m2 g-1)
than GO (890 m2g-1) [45]. Possibly, the larger surface area of rGO provides the space
for MSCs to signal extracellular cues to neighboring cells. In standard cell culture, cells
do not thrive in cramped environments, therefore it is important to design biomaterials
with large surface areas for optimal cell communication and functioning.
In the future, GO and rGO scaffolds should be compared in in vivo bone defects to
determine the optimal bone regenerative outcome. Additionally, this information can be
used for ‘priming’ MSCs prior to transplantation. For example, MSCs could be cultured
on rGO for 3 days, frozen down, and then implanted into an in vivo bone defect. If
successful, this could eliminate the extra variable of a scaffold which has its own
challenges (i.e., production, toxicity, degradability, etc.). However, before that project
can be developed, understanding the gene expression of cells exposed to graphene
substrates, such as this study provides, is necessary.
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CONCLUSION
In this study, we examined the genetic regulation of MSCs undergoing bone
differentiation on GO and rGO substrates, including genes related to transcriptional
regulation, osteoblast-related, the ECM, cell adhesion, growth factors, BMP & SMAD
signaling, angiogenic factors, and MMPs. We found that both GO and rGO substrates
supported osteogenic gene expression of MSCs. However, there were differences in the
gene expression profiles between cells cultured on GO and rGO. Most notably, a headto-head comparison showed that genes important to the osteoblast differentiation
process were robust on rGO than GO. In the future, this information can be translated to
in vivo models that compare GO and rGO scaffolds for optimal bone regeneration.
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APPENDIX
Table 3.1. Gene expressions of AD-MSCs cultured on GO over time. CT values for each gene were
normalized using a housekeeping gene and then the fold changes were calculated by using Day 3
expression as the control and Day 7 or Day 21 as the tested groups. NC = No Change; ND = NonDetectable.

Gene Description

Transcriptional Regulation
Distal-less homeobox 5
Runt-related transcription factor 2
SRY (sex determining region Y)-box 9
Sp7 transcription factor
Osteoblast-Related
Alkaline phosphatase, liver/bone/kidney
Bone gamma-carboxyglutamate (gla) protein
Phosphate regulating endopeptidase homolog, Xlinked
Secreted phosphoprotein 1
Extracellular Matrix Markers
Biglycan
Collagen, type I, alpha 1
Collagen, type I, alpha 2
Collagen, type III, alpha 1
Collagen, type V, alpha 1
Collagen, type X, alpha 1
Collagen, type XIV, alpha 1
Collagen, type XV, alpha 1
Fibronectin 1
Cellular Adhesion
Cadherin 11, type 2, OB-cadherin (osteoblast)
Intercellular adhesion molecule 1
Integrin, alpha 1
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2
receptor)
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit
of VLA-3 receptor)
Integrin, beta 1 (fibronectin receptor, beta
polypeptide, antigen CD29 includes MDF2,
MSK12)
Vascular cell adhesion molecule 1

Symbol

Fold
Change
(Day 3 to
Day 7)

Fold
Change
(Day 3 to
Day 14)

Fold
Change
(Day 3 to
Day 21)

ND

ND
3.41
NC
3.00

DLX5
RUNX2
SOX9
SP7

NC
0.57
NC

ND
NC
NC
NC

ALPL
BGLAP

NC
NC

3.89
1.73

3.28
2.23

PHEX

NC

1.52

3.03

SPP1

0.43

NC

1.51

BGN
COL1A1
COL1A2
COL3A1
COL5A1
COL10A1
COL14A1
COL15A1
FN1

0.22
0.42
NC
0.70
0.22
NC
2.60
0.21
0.31

0.36
0.34
NC
0.67
0.32
NC
7.03
0.30
NC

NC
NC
NC
NC
NC
8.55
10.46
NC
NC

CDH11
ICAM1
ITGA1

NC
1.36
0.48

NC
3.53
NC

1.73
6.67
1.82

ITGA2

0.25

0.39

NC

ITGA3

0.12

NC

3.97

ITGB1

0.45

NC

NC

VCAM1

NC

1.95

NC
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Table 3.1. Continued.
Gene Description
BMP and SMAD Signaling
Bone morphogenetic protein 1
Bone morphogenetic protein 2
Bone morphogenetic protein 4
Bone morphogenetic protein 6
Activin A receptor, type I
Bone morphogenetic protein receptor, type IA
Bone morphogenetic protein receptor, type IB
Bone morphogenetic protein receptor, type II
SMAD family member 1
SMAD family member 2
SMAD family member 3
SMAD family member 4
SMAD family member 5
Growth Factors
Epidermal growth factor
Epidermal growth factor receptor
Fibroblast growth factor 1 (acidic)
Fibroblast growth factor 2 (basic)
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Growth differentiation factor 10
Insulin-like growth factor 1 (somatomedin C)
Insulin-like growth factor 2 (somatomedin A)
Insulin-like growth factor 1 receptor
Transforming growth factor, beta 1
Transforming growth factor, beta 2
Transforming growth factor, beta 3
Transforming growth factor, beta receptor 1
Transforming growth factor, beta receptor II
(70/80kDa)
Tumor necrosis factor
Angiogenic Factors
Fms-related tyrosine kinase 1 (vascular endothelial
growth factor/vascular permeability factor receptor)
Platelet-derived growth factor alpha polypeptide
Vascular endothelial growth factor A
Vascular endothelial growth factor B
Bone Remodeling
Matrix metallopeptidase 2
Matrix metallopeptidase 8
Matrix metallopeptidase 9
Matrix metallopeptidase 10

Symbol

Fold
Change
(Day 3 to
Day 7)

Fold
Change
(Day 3 to
Day 14)

Fold
Change
(Day 3 to
Day 21)

BMP1
BMP2
BMP4
BMP6
ACVR1
BMPR1A
BMPR1B
BMPR2
SMAD1
SMAD2
SMAD3
SMAD4
SMAD5

0.45
NC
NC
0.36
NC
NC
NC
NC
NC
NC
NC
NC
NC

NC
4.13
3.44
NC
NC
NC
2.65
NC
NC
NC
NC
NC
NC

NC
5.34
5.24
0.33
3.26
2.65
8.75
1.67
3.29
2.77
3.70
2.57
2.11

EGF
EGFR
FGF1
FGF2
FGFR1
FGFR2
GDF10
IGF1
IGF2
IGF1R
TGFB1
TGFB2
TGFB3
TGFBR1

NC
NC
0.26
0.03
NC
0.19
0.13
NC
NC
NC
0.45
NC
NC
NC

NC
1.82
0.55
0.47
NC
0.22
0.75
2.24
NC
NC
NC
NC
NC
NC

3.08
4.76
NC
NC
2.79
NC
0.40
1.66
7.28
1.88
1.78
3.28
3.28
1.82

TGFBR2

NC

2.51

2.66

TNF

NC

8.17

10.56

FLT1

NC

NC

NC

PDGFA
VEGFA
VEGFB

NC
NC
NC

NC
NC
1.53

NC
1.31
4.66

MMP2
MMP8
MMP9
MMP10

1.67
NC
NC
2.10

3.36
11.96
2.70
6.29

6.23
19.12
1.15
5.15
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Table 3.2. Gene expressions of AD-MSCs cultured on rGO over time. CT values for each gene were
normalized using a housekeeping gene and then the fold changes were calculated by using Day 3
expression as the control and Day 7 or Day 14 as the tested groups. NC = No Change.

Gene Description

Symbol

Fold
Change
(Day 3
to Day
7)

Fold
Change
(Day 3
to Day
14)

Transcriptional Regulation
Distal-less homeobox 5
Runt-related transcription factor 2
SRY (sex determining region Y)-box 9
Sp7 transcription factor

DLX5
RUNX2
SOX9
SP7

NC

NC

NC
0.52
NC

NC
0.52
0.40

Osteoblast-Related
Alkaline phosphatase, liver/bone/kidney
Bone gamma-carboxyglutamate (gla) protein
Phosphate regulating endopeptidase homolog, X-linked
Secreted phosphoprotein 1

ALPL
BGLAP
PHEX
SPP1

4.66
0.69
NC
0.34

3.43
0.42
NC
0.41

BGN
COL1A1
COL1A2
COL3A1
COL5A1
COL10A1
COL14A1
COL15A1
FN1

0.79
1.26
1.40
1.21

1.84
1.75
1.55
1.81

NC

NC

NC
2.36
0.54
0.63

NC
2.90
NC
0.74

CDH11
ICAM1
ITGA1
ITGA2

0.61
0.61
0.40
0.14

0.58
NC
0.27
0.24

ITGA3

0.35

0.32

ITGB1

NC

0.64

VCAM1

4.30

5.13

Extracellular Matrix Markers
Biglycan
Collagen, type I, alpha 1
Collagen, type I, alpha 2
Collagen, type III, alpha 1
Collagen, type V, alpha 1
Collagen, type X, alpha 1
Collagen, type XIV, alpha 1
Collagen, type XV, alpha 1
Fibronectin 1
Cellular Adhesion
Cadherin 11, type 2, OB-cadherin (osteoblast)
Intercellular adhesion molecule 1
Integrin, alpha 1
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
receptor)
Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen
CD29 includes MDF2, MSK12)
Vascular cell adhesion molecule 1
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Table 3.2. Continued.

Gene Description

BMP and SMAD Signaling
Bone morphogenetic protein 1
Bone morphogenetic protein 2
Bone morphogenetic protein 4
Bone morphogenetic protein 6
Activin A receptor, type I
Bone morphogenetic protein receptor, type IA
Bone morphogenetic protein receptor, type IB
Bone morphogenetic protein receptor, type II
SMAD family member 1
SMAD family member 2
SMAD family member 3
SMAD family member 4
SMAD family member 5
Growth Factors
Epidermal growth factor
Epidermal growth factor receptor
Fibroblast growth factor 1 (acidic)
Fibroblast growth factor 2 (basic)
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Growth differentiation factor 10
Insulin-like growth factor 1 (somatomedin C)
Insulin-like growth factor 2 (somatomedin A)
Insulin-like growth factor 1 receptor
Transforming growth factor, beta 1
Transforming growth factor, beta 2
Transforming growth factor, beta 3
Transforming growth factor, beta receptor 1
Transforming growth factor, beta receptor II (70/80kDa)
Tumor necrosis factor
Angiogenic Factors
Fms-related tyrosine kinase 1 (vascular endothelial growth
factor/vascular permeability factor receptor)
Platelet-derived growth factor alpha polypeptide
Vascular endothelial growth factor A
Vascular endothelial growth factor B
Bone Remodeling
Matrix metallopeptidase 2
Matrix metallopeptidase 8
Matrix metallopeptidase 9
Matrix metallopeptidase 10

Symbol

Fold
Change
(Day 3
to Day
7)

Fold
Change
(Day 3
to Day
14)

BMP1
BMP2
BMP4
BMP6
ACVR1
BMPR1A
BMPR1B
BMPR2
SMAD1
SMAD2
SMAD3
SMAD4
SMAD5

0.60
0.14
0.64
0.16
0.64
0.70
0.54
NC
0.76
0.65
NC
0.61
0.58

NC
NC
0.41
0.21
0.63
0.48
0.40
NC
NC
0.58
NC
0.46
0.63

EGF
EGFR
FGF1
FGF2
FGFR1
FGFR2
GDF10
IGF1
IGF2
IGF1R
TGFB1
TGFB2
TGFB3
TGFBR1
TGFBR2
TNF

2.29
0.53
0.49
NC
0.62
NC
0.56
0.73
NC
0.41
0.53
NC
0.43
0.69
NC
NC

NC
0.50
0.62
0.75
NC
NC
0.60
1.89
NC
0.43
0.60
2.36
0.43
NC
0.54
NC

0.23

NC

0.48
0.52
0.57

0.62
0.48
0.50

0.65
NC
NC
0.11

0.86
4.42
3.14
0.35

FLT1
PDGFA
VEGFA
VEGFB
MMP2
MMP8
MMP9
MMP10
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Table 3.3. Gene expressions of AD-MSCs cultured on rGO in comparison to AD-MSCs cultured on GO for
either 3, 7, or 14 days. CT values for each gene were normalized using a housekeeping gene and then the
fold changes were calculated by using GO as the control and rGO as the tested group. NC = No Change;
ND = Non-Detectable.

Gene Description

Transcriptional Regulation
Distal-less homeobox 5
Runt-related transcription factor 2
SRY (sex determining region Y)-box 9
Sp7 transcription factor
Osteoblast-Related
Alkaline phosphatase, liver/bone/kidney
Bone gamma-carboxyglutamate (gla) protein
Phosphate regulating endopeptidase homolog, Xlinked
Secreted phosphoprotein 1
Extracellular Matrix Markers
Biglycan
Collagen, type I, alpha 1
Collagen, type I, alpha 2
Collagen, type III, alpha 1
Collagen, type V, alpha 1
Collagen, type X, alpha 1
Collagen, type XIV, alpha 1
Collagen, type XV, alpha 1
Fibronectin 1
Cellular Adhesion
Cadherin 11, type 2, OB-cadherin (osteoblast)
Intercellular adhesion molecule 1
Integrin, alpha 1
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2
receptor)
Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
VLA-3 receptor)
Integrin, beta 1 (fibronectin receptor, beta
polypeptide, antigen CD29 includes MDF2, MSK12)
Vascular cell adhesion molecule 1

Symbol

Fold
Change
(Day 3)

Fold
Change
(Day 7)

Fold
Change
(Day 14)

DLX5
RUNX2
SOX9
SP7

NC

ND

ND

3.94
2.79
NC

2.58
2.51

1.64
1.49
0.48

ALPL
BGLAP

0.35
1.43

2.07
NC

0.31
0.34

PHEX

NC

NC

NC

SPP1

NC

NC

0.68

BGN
COL1A1
COL1A2
COL3A1
COL5A1
COL10A1
COL14A1
COL15A1
FN1

0.43
0.34
0.55

1.54

NC
NC
NC
NC

1.32
2.64

2.17
1.76
NC
2.06
2.12
NC
0.46
1.84
NC

NC

NC
NC

0.43

NC
NC
NC

NC

1.71

NC

NC
NC

CDH11
ICAM1
ITGA1

2.23
2.08

1.75

0.61
NC
NC

ITGA2

6.42

3.71

3.94

ITGA3

NC

2.27

0.78

ITGB1

NC

2.57

1.37

VCAM1

0.10

0.53

0.25
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Table 3.3. Continued.
Gene Description
BMP and SMAD Signaling
Bone morphogenetic protein 1
Bone morphogenetic protein 2
Bone morphogenetic protein 4
Bone morphogenetic protein 6
Activin A receptor, type I
Bone morphogenetic protein receptor, type IA
Bone morphogenetic protein receptor, type IB
Bone morphogenetic protein receptor, type II
SMAD family member 1
SMAD family member 2
SMAD family member 3
SMAD family member 4
SMAD family member 5
Growth Factors
Epidermal growth factor
Epidermal growth factor receptor
Fibroblast growth factor 1 (acidic)
Fibroblast growth factor 2 (basic)
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor 2
Growth differentiation factor 10
Insulin-like growth factor 1 (somatomedin C)
Insulin-like growth factor 2 (somatomedin A)
Insulin-like growth factor 1 receptor
Transforming growth factor, beta 1
Transforming growth factor, beta 2
Transforming growth factor, beta 3
Transforming growth factor, beta receptor 1
Transforming growth factor, beta receptor II
(70/80kDa)
Tumor necrosis factor
Angiogenic Factors
Fms-related tyrosine kinase 1 (vascular endothelial
growth factor/vascular permeability factor receptor)
Platelet-derived growth factor alpha polypeptide
Vascular endothelial growth factor A
Vascular endothelial growth factor B
Bone Remodeling
Matrix metallopeptidase 2
Matrix metallopeptidase 8
Matrix metallopeptidase 9
Matrix metallopeptidase 10

Symbol

BMP1
BMP2
BMP4
BMP6
ACVR1
BMPR1A
BMPR1B
BMPR2
SMAD1
SMAD2
SMAD3
SMAD4
SMAD5

Fold
Chang
(Day 3)

Fold
Change
(Day 7)

Fold
Change
(Day 14)

NC

1.87
5.68

1.57
7.24
0.23
2.27
NC
NC
NC
NC
NC
0.77
NC
0.67
NC

48.06
1.90
9.56
1.93
1.76
5.21
NC
NC

NC

4.38
1.18
1.41
2.61
1.52
NC

1.69
1.39
1.84
1.69

1.45

NC

NC
NC

NC

1.41
NC

NC

NC

10.39
1.66

5.88
NC

NC
0.61
NC
1.28
1.57
0.44
0.42
1.84
NC
1.38
NC
1.73
2.95
1.41

2.69

2.85

0.58

NC

NC

0.11

FLT1

NC

0.26

1.51

PDGFA
VEGFA
VEGFB

1.80
NC
NC

NC
NC

0.83

1.75
0.77
0.40

MMP2
MMP8
MMP9
MMP10

3.45
11.21
3.38
33.21

1.34
4.18
4.72
1.71

NC
4.14
3.93
1.84

EGF
EGFR
FGF1
FGF2
FGFR1
FGFR2
GDF10
IGF1
IGF2
IGF1R
TGFB1
TGFB2
TGFB3
TGFBR1
TGFBR2
TNF

2.19
NC
NC

2.49
0.13
0.52
2.18
4.69
2.54
1.78

2.12
19.56
1.79
NC
NC

1.32
NC

1.89
2.09
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CHAPTER IV:
NEXT GENERATION RNA SEQUENING REVEALS GENETIC
ALTERATIONS DURING CHEMICALLY INDUCED BONE
DIFFERENTIATION OF MESENCHYMAL STEM CELLS FROM A POSTMENOPAUSE ANIMAL MODEL
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ABSTRACT
The lack of mesenchymal stem cell (MSC) differentiation contributes to challenges in
bone repair of age-related bone degenerative diseases. However, the genes involved in
this process are not clearly defined. We therefore obtained MSCs from the postmenopause ovariectomized rat model, which parallels human bone degeneration.
MSCs from both control (con-MSCs) and ovariectomized (ovx-MSCs) animals were
exposed to an osteogenic differentiation cocktail for 7 and 21 days. Results confirmed
ovx-MSCs failed to respond to osteogenic differentiation in comparison to con-MSCs.
We then examined a genome-wide expression profile of both MSC groups via RNA
sequencing. Genes important to bone differentiation were clustered as either cell
adhesion (integrins and cadherins), ECM (collagens, glycoproteins, and proteoglycans),
growth factors (estrogens, androgens, BMPs, TGFs, FGFs, PDGFs, VEGFs, IGFs, and
EGFs), Wnt-Catenin signaling (Wnts, Catenins, Frizzelds, SMADs), cell signaling
factors (MAPKs, PI3Ks, Akts), mineralization (calcium and phosphatase-regulated
genes), or bone remodeling (MMPs). For each cluster, gene expressions were
examined using day 7 as the control and day 21 as the tested group. Analysis showed
the percentage of upregulated clusters were consistently highest within con-MSCs.
Additionally, we specify the genes that did not share commonality between con-MSCs
and ovx-MSCs. Overall, this data suggests that following menopause, multiple genes
affect MSC bone differentiation, thereby contributing to the onset of bone degeneration.
This information is necessary for future drug targets and gene editing strategies that
could treat or prevent bone degeneration.
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INTRODUCTION
Cell-based therapies are under thorough investigation for treating bone degenerative
diseases. The preferred cell source in stimulating new bone are mesenchymal stem
cells (MSCs) as they have the potential to undergo differentiation into various lineages
and do not demonstrate immunological rejection or abnormal growth patterns [1, 2].
Traditionally, MSCs are either derived autologously (from the patient in need) or as
allogenic cells (from an appropriate donor) and then implanted with the expectation of
undergoing differentiation and/or triggering pathways to heal the bone defect [3].
However, both autologous and allogenic MSCs require months of strategic testing and
planning, thereby delaying those needing immediate treatment. Additionally, autologous
MSCs from patients with bone degenerative diseases are invalid due to cellular
senescence and other non-modifiable risk factors (i.e. age, sex, history, etc.) [4, 5].
Therefore, the focus should be on targeting endogenous MSCs that restores activity
within chronic bone conditions such as osteoarthritis, osteopenia, and osteoporosis.
However, this strategy will not be pharmaceutically effective until there is thorough
characterization of MSCs from diseased bone. In other words, examining the behavior
of MSCs derived from diseased bone will allow new developments of effective treatment
strategies.
The ovariectomized (OVX) rat is an FDA approved model that mimics bone
degeneration associated with osteoporosis in humans [6, 7]. The model is characterized
by low bone mass and structural deterioration of bone tissue leading to bone fragility
and thus, an increased susceptibility to fractures. It has been demonstrated that
ovariectomy (or estrogen deficiency), prevents the synthesis of mineralized matrix and
expression of osteocyte – specific genes in MSCs isolated from OVX rats [8, 9]. Ren et
al., 2020 showed that bone marrow-derived MSCs (BM-MSCs) from OVX rats display
down regulation of osteogenic differentiation supported by changes in ALP, OCN and
OPN [8]. Interestingly, Boelloni et al., 2014 found that adipose tissue – derived MSCs
(AD-MSCs) from OVX rats have higher osteogenic potential than BM-MSCs [10],
thereby suggesting that AD-MSCs are more appropriate for autologous cell therapy of
bone diseases post-menopause. In all these studies, standard protocols of alizarin red
staining and single gene traditional PCRs were used to demonstrate in vitro
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osteogenesis/bone mineralization and changes in osteogenic gene expression patterns,
respectively.
Next – generation high throughput RNA sequencing introduced roughly a decade ago,
provides insight into the transcriptome of a cell in a given physiological condition [11,
12]. RNA-sequencing provides higher coverage and greater resolution of the dynamic
nature of the transcriptome. This technique thus, presents significant advantages over
traditional Sanger sequencing or microarray-based transcriptomic approaches and
hence, could yield valuable information about the MSCs isolated from an OVX rat
relative to MSCs isolated from matched sham controls (con-MSCs). Therefore, our
primary goal was to isolate MSCs from the OVX rat model and understand the genetic
behavior following exposure to a chemically induced bone differentiation cocktail. We
hypothesized that osteoblast differentiation of MSCs derived from OVX animals (ovxMSCs) would be affected, and that RNA sequencing would reveal the genetic
alterations during this process. This information identifies specific molecular gene
transcripts and protein isoforms important for osteoblast development in the OVX
condition and thus, will help develop new pharmaceutical drugs and bone tissue
engineering strategies.

METHODS
Animal Model
All procedures were approved by the University of Tennessee Institutional Animal Care
and Use Committee. 12 female Sprague-Dawley rats were purchased from Charles
River (Wilmington, MA) and either sham operated (n=6) or ovariectomized (OVX) (n=6).
The animals were housed in pairs and acclimatized for one week at the University of
Tennessee Medical Center, Animal Facility. Following acclimatization, animals were
housed individually to control for diet consumption.
All rats were fed a commercially available low calcium diet (Envigo,Indianapolis, ID).
The formula consisted of casein (200 g/Kg), L-cystine (3.0 g/Kg), sucrose (342.188
g/Kg), corn starch (320.0 g/Kg), soybean oil (60 g/Kg), cellulose (40 g/Kg), mineral mix
(Ca-P deficient) (13.37 g/Kg), potassium phosphate (monobasic) (11.43 g/Kg), vitamin
mix (10.0 g/Kg), and ethoxyquin, an antioxidant (0.012 g/Kg). The casein contributed
~0.01% calcium or less. The diet also contained ~0.4% phosphorus and 2200 IU
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vitamin D/Kg diet. Food was stored at 4°C and used within 6 months of purchasing.
Each rat was fed 210 g (+/- 5 g) of diet every 7 days according to manufacturer
recommendations. The rats consumed this diet for 8 weeks, with food intake and body
weights recorded weekly.
Serum CTX-1/TRAP5b Ratio
On the day of sacrifice, whole blood was extracted from the apex of the left ventricle
and aliquoted into EDTA tubes for serum collection. Samples were placed on ice for
approximately one hour, and then centrifuged at 300 X G for 10 min and supernatant
was stored at -80°C before analysis.
The ratio of C-telopeptide of type I collagen (CTX-1) to tartrate-resistant acid phosphate
isoform 5b (TRAP5B) was analyzed using enzyme-linked immunosorbent assays
(ELISA). CTX-1 is a serum biomarker of osteoclast activity while TRAP5b is an enzyme
that reflects osteoclast number [13-15]. The average activity of a single osteoclast is
defined as the ratio of CTX-1:TRAP5b, both of which are expressed in blood and
provides stronger evidence of bone resorption rather than examining either marker
alone [16, 17]. Rat CTX-1 and TRAP5b ELISA kits were purchased from Cusabio
Biotechnology (Wuhan, China) and Immunodiagnostic Systems (East Boldon, United
Kingdom), respectively. CTX-1 and TRAP5b were analyzed and quantitated from serum
samples according to the manufacturer’s instructions. A resorption index was created by
dividing CTX-1 (pg/mL) by TRAP5b (U/L) and was compared between sham and OVX
serum.
Isolation of Rat MSCs
Animals were sacrificed using a CO2 chamber and the femur bones were immediately
harvested for MSC isolation of the bone marrow as described in similar reports [18, 19].
The femurs were first rinsed with PBS before clipping the ends of the bone. An 18gauge needle was used to extrude the bone marrow and rinsed into a collection tube
using a syringe filled with media. A cell pellet was collected from centrifugation at 1000
rpm for 5 min and then re-suspended with 5.5 mL media. Cells were filtered with a 70
m strainer, then 2 mL of media was added and the filter process was repeated to
ensure full collection. In general, cells from 2 animals were combined to obtain sufficient
numbers prior to in vitro experiments. Cells were grown to 80—90% confluency and
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then harvested with 0.05% trypsin for cryopreservation (80% FBS, 10% DMEM-F12,
and 10% DMSO) or re-seeded for expansion in growth media (DMEM/F12, 10% FBS,
1% penicillin-streptomycin and 1% amphotericin B). All experiments were performed
using cells from passage 2–6.
Characterization of Rat MSCs
Rat MSC characterizations were performed as previously reported for rat and human
MSCs [20]. MSCs are identified by the expression of specific cluster-of-differentiation
(CD) markers, found at the cell surface [21]. Specific markers tested were CD11b/c,
CD29, CD44, CD45, CD73, CD90.All markers tested are recognized by the
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
Therapy [21]. All antibodies were used at concentrations as per the manufacturer’s
recommendations (Biolegend, San Diego, CA). Stained cells were assayed on BD
FACS Calibur and expression was measured and analyzed by FlowJo software.
Differentiation of Rat MSCs into Osteoblasts
Osteogenic differentiation was carried out according to standard method as reported
earlier [22, 23]. For experimental conditions, cells were collected using 0.05% trypsin
and seeded onto tissue culture dishes in growth media. The cells were incubated at
37°C, 5% CO2 and induced towards osteogenesis with media that was supplemented
with 10 mM β-glycerol phosphate, 50 µM ascorbic acid, and 100 nm dexamethasone.
The osteogenic media was replaced every other day up to 21 days.
To determine mineralization and visualize any morphological changes, cells were
stained with alizarin red after 21 days of osteogenic induction. Mineralization was
evaluated by quantitation of Alizarin red staining as described earlier [24-26]. Cells were
imaged on the Leica DMi1 Inverted Microscope with LAS V4.12 software. All pictures
were taken on the same day under the same parameters for brightness, contrast,
saturation, resolution, and magnification.
RNA Extraction
To evaluate changes in gene expression during osteogenesis, cells were harvested
after 7 and 21 days of osteogenic induction. Total RNA was extracted using the
RNeasy® Mini Kit (Qiagen, Germantown, MD) and RNA integrity was evaluated using
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the RNA 6000 Nano Kit and 2100 Bioanalyzer system (Agilent Techologies, Santa
Clara, CA) as previously reported [26, 27].
RNA Sequencing
Library Construction and Sequencing
The total RNA preparation and deep sequencing of the whole transcriptome library were
performed by Novogene Corporation Inc. (Sacramento, CA). A total amount of 1 µg
RNA per sample was used as input material for the RNA sample preparations.
Sequencing libraries were generated using NEBNext® UltraTM RNA Library Prep Kit for
Illumina® (NEB, USA) and index codes were added to attribute sequences to each
sample. The clustering of the index-coded samples was performed on a cBot Cluster
Generation System using PE Cluster Kit cBot-HS (Illumina). After cluster generation, the
library preparations were sequenced on an Illumina platform and paired-end reads were
generated.
Quality Control
Following sequencing, raw reads were processed through fastp whereby clean reads
were obtained by removing any read containing adapter and poly-N sequences. After
filtering, sequencing error rate check (Q20 and Q30) and GC content of the clean data
were calculated. The paired-end clean reads were then mapped to the reference
genome using HISAT2 software. The reference genome and gene model annotation
files were directly downloaded from genome website browser (NCBI/UCSE/Ensembl).
Data Analysis
All gene expressions were reported in a Microsoft Excel spreadsheet. Genes of interest
were searched with a key phrase (i.e. bone morphogenetic protein) and all isoforms
were clustered within a group. We evaluated gene clusters well established in the bone
differentiation process and thereby categorized these clusters as either cell adhesion
(integrins and cadherins); ECM (collagens, glycoproteins, and proteoglycans); growth
factors (estrogens, androgens, BMPs, TGFs, FGFs, PDGFs, VEGFs, IGFs, EGFs); Wnt
/ Catenin signaling (Wnts, Frizzleds, Catenins, SMADs); cell signaling factors (MAPKs,
PI3Ks, Akts); mineralization (calcium and phosphatase-regulated genes); and bone
remodeling genes (MMPs). All genes within each cluster were then sorted between
significant and non-significant expression. Because these clusters are suggested to
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have increased activity during bone differentiation [28-34], we focused on upregulated
gene expression using day 7 as the control and day 21 as the tested group within both
con-MSCs and ovx-MSCs.
Statistical Analysis
The average body weight, osteoclast activity, and mineralization quantification were
tested with the 2-Tailed Student’s T-test; data is presented as standard error of the
mean. For RNA sequencing, 2 biological replicates per condition were analyzed.
Featurecounts was used to count the number of reads mapped to each gene. The
RPKM (Reads Per Kilobase of exon model per Million mapped reads) was used to
normalize the sequencing depth and gene length for the reads count. Differential
expression analysis between groups (with biological replications) was performed using
DESeq2 R package, which provides statistical information using a model based on the
negative binomial distribution. The resulting P values were adjusted using the Benjamini
and Hochberg’s approach for controlling the False Discovery Rate (FDR). Genes with
an adjusted P value < 0.05 were assigned as differentially expressed and the
log2(foldchange) of 1 were set as the threshold, whereby expression >1 and <1 indicated
positive and negative upregulation, respectively. All sample values were related to the
control at Day 7 and presented as the percentage of upregulated genes within each
cluster.

RESULTS
OVX animals have higher body weights and osteoclast activity than control
animals
All animals demonstrated healthy eating patterns and showed no signs of stress. On the
day of sacrifice, final body weights of OVX rats were significantly higher than the control
group (Figure 4.1A), which is consistent with previous reports [8, 35]. Supportively,
ELISA analysis of serum samples showed a greater CTX-1:TRAP5b ratio in OVX
animals (117.12) in comparison to the control (52.61) (Figure 4.1B). These results
confirmed that OVX animals had greater bone resorption activity than that of control
animals.
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Rat bone marrow – derived cells express specific MSC markers
Following cell isolation and expansion, both the con - and ovx – MSCs showed >90%
expression of CD29 and CD90 and >70% expression of CD73 (Figure 4.2). In contrast,
there was no expression (<5%) of CD11b/c and CD45. These data confirmed that the
cells isolated and expanded from both the control and OVX rats were indeed MSCs.
Higher Bone Mineralization in con - MSCs
To evaluate the osteogenic potential, both con-MSCs and ovx-MSCs were exposed to
osteogenic differentiation media up to 21 days. Cell morphology and in vitro
differentiation/mineralization was assessed by standard Alizarin red staining and
quantitated as reported earlier [26, 36]. Both con – and OVX – MSCs showed cell
clustering and formation of nodules indicating in vitro mineralization (Figure 4.3A).
However, discrete nodules and larger clusters of cells were observed in con-MSCs only,
indicating greater osteogenic differentiation. Additionally, ovx-MSCs morphologically
resembled control cells that were not exposed to differentiation media (inset Figure
4.3A). Quantitation of the alizarin red stain confirmed that ovx-MSCs had a significant
decrease in calcium content in comparison to con-MSCs (Figure 4.3B). These results
confirmed that even though ovx-MSCs express specific CD markers, and contain
progenitors with osteogenic potential, the osteoblast differentiation process is inferior to
con-MSCs.
High quality RNA was isolated from MSCs
Prior to sequencing, RNA integrity was evaluated as described earlier [26]. Intact RNA
is recognized by specific ribosomal subunits: 18S and 28S; therefore, any degradation
of RNA would lack these subunits, and provide uneven gene coverage thus, making the
RNA less efficient and unsuitable for RNA sequencing. The RNA integrity number (RIN)
measured on a scale from 1 – 10 is used as an index for RNA quality and suitability for
RNA sequencing. RIN values < 6 represent low quality RNA [12]. In this study, RIN
values were > 8.5 for all RNA samples isolated at both time points from both cell
sources.
Control MSCs express more significantly changed genes
After comparing from day 7 to day 21, RNA sequencing results showed the expression
of 13,855 genes in con-MSCs compared to 17,409 genes in ovx-MSCs. Of these, 41%
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genes in con-MSCs were significantly altered compared to only 28% in ovx-MSCs,
suggesting more genetic changes in con-MSCs.
Table 4.2 describes specific genes from each cluster that were upregulated in conMSCs, but not in ovx-MSCs.
OVX derived MSCs express downregulation of ALPL
MSCs typically undergo osteogenesis in vitro over a period of 21-28 days when
exposed to a dexamethasone/beta glycerophosphate and ascorbic acid cocktail [26].
Hence, genetic expression of osteogenic markers such as transcription factors (DLX5,
RUNX2, and SOX9) and osteoblast/osteocyte markers (ALPL and SPP1) were
examined over time (day 7 to day 21) within con-MSCs and ovx-MSCs. RUNX2 and
SPP1 were upregulated confirming that the con-MSCs undergo in vitro osteogenesis
and mineralization as expected (Table 4.1). Similarly, ovx-MSCs expressed
upregulation in RUNX2 and SPP1, but downregulation of ALPL, the prominent gene of
bone mineralization. Overall, this suggests that ovx-MSCs contain osteoprogenitors, but
lack the ability to undergo mineralization, further supporting the decreased
mineralization content demonstrated above.
Control and OVX derived MSCs reveal differences in cell adhesion, ECM, and
growth factor genes
As single gene reactions are not representative of a genome that expresses thousands
of genes, we next examined gene clusters well established in the bone differentiation
process. Here we first examined genes related to cell adhesion and the ECM, which are
the early foundation of bone differentiation. For the ECM, con-MSCs expressed more
upregulated collagens (44%), glycoproteins (34%), and proteoglycans (20%), compared
to ovx-MSCs (Figure 4.4B).
Additionally, the integrin and cadherin genes are important cell adhesion molecules for
early cell communication. More specifically, the integrins are receptors that bind to the
ECM and regulate both intracellular and extracellular signals, while cadherins bind cells
and promote cell-to-cell communication [28, 37, 38]. Con-MSCs expressed upregulated
integrin genes by 52%, compared to only 41% in ovx-MSCs (Figure 4.4A). Additionally,
con-MSCs expressed upregulated cadherin genes by 43%, compared to only 26% in
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ovx-MSCs. Overall, these data suggest that ovx-MSCs express fewer initiators of the
bone differentiation process.
With establishment of cell adhesion and ECM, growth factor signaling stimulates a
chain-of-command beginning at the membrane, through the cytosol, and into the
nucleus for genetic transcription and ultimately protein synthesis. We therefore
investigated several growth factor clusters including sex hormones (estrogens and
androgens), BMPs, TGFs, FGFs, PDGFs, VEGFs, IGFs, and EGFs. Consistent patterns
were found within most growth factor clusters (Figure 4.4C). For example, con-MSCs
and ovx-MSCs expressed upregulated BMPs by 44% and 38%, TGFs by 53% and 47%,
FGFs by 40% and 14%, and PDGFs by 75% and 25%, respectively. Other growth
factors investigated were VEGFs, IGFs, and EGFs, which showed similar expression
patterns between both cell groups.
Interestingly and as expected, we confirmed that the con-MSCs upregulated 33% of
estrogens and androgens compared to 0% for both clusters in ovx-MSCs (Figure 4.4D).
The lack of estrogen production within ovx-MSCs was expected as these cells were
derived from ovariectomized animals, further confirming the OVX state of the animals.
Control and OVX derived MSCs reveal differences in Wnt-Catenin Signaling
A prominent signaling pathway in bone development is the Wnt/Catenin pathway which
includes several Wnt, frizzled, catenin, and SMAD isoforms. Con-MSCs and ovx-MSCs
expressed upregulated Wnts by 17% and 9%, frizzleds by 36% and 25%, catenins by
71% and 50%, and SMADs by 45% and 33%, respectively (Figure 4.5). Overall, these
clusters were consistently lower in ovx-MSCs, suggestive of altered Wnt/Catenin
signaling following bone differentiation cues.
Control and OVX derived MSCs reveal differences in cell differentiation genes
There are several other intracellular signaling molecules involved in cell survival,
proliferation, and bone differentiation. These molecules communicate signals into the
nucleus for transcriptional activity, which are often regulated by MAPK, PI3K, and Akt.
In our analysis, we find differences in upregulated MAPK genes which was 26% in conMSCs, but 19% in ovx-MSCs (Figure 4.6). Additionally, upregulated PI3K genes was
expressed by 36% in con-MSCs and 31% in ovx-MSCs. In contrast, a similar
expression pattern was observed for Akts within these cell groups. Overall, this data
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suggests that con-MSCs have more intracellular signaling mechanisms occurring
compared to the ovx-MSCs.
Control and OVX derived MSCs reveal differences in calcium and phosphatase
regulated genes
MSC differentiation and subsequent mineralization does not occur without the presence
of calcium and phosphate, which together forms hydroxyapatite, the inorganic portion of
bone. Because some genes are regulated by the presence of calcium and phosphate
groups, it would be presumed that mineralized cells would express more genes
controlled by calcium and phosphatases. In our analysis, con-MSCs expressed
upregulated calcium-regulated genes by 21%, compared to only 11% in ovx-MSCs
(Figure 4.7). Additionally, we found that con-MSCs expressed upregulated
phosphatases by 31%, compared to 22% in ovx-MSCs. This data supports that ovxMSCs lack mineralization, despite being in the presence of osteo-inducers.
Table 4.2 describes the specific calcium and phosphatase-regulated genes that were
upregulated in con-MSCs, but not in ovx-MSCs.
Control and OVX derived MSCs reveal differences in bone remodeling genes
Following bone mineralization, matrix metallopeptidases (MMPs) are enzymes critical to
bone maintenance and remodeling [34, 39]. As expected, we found that con-MSCs
expressed upregulated MMPs by 77%, compared to only 38% in ovx-MSCs (Figure
4.8). Overall, this data supports that MMP expression is less active in cells derived from
the OVX model and may be an important target for future therapies.

DISCUSSION
The progression of age-related bone degenerative diseases is largely contributed by
lack of adult, mesenchymal stem cell differentiation [4, 5, 40]. There are many theories
for this inadequate bone differentiation (i.e., hormonal changes, decreased calcium
absorption), but the overall issue is a bone remodeling imbalance whereby bone
resorption activity outpaces new bone formation led by MSCs [41]. As cell behavior is
controlled by genes, it is necessary to compare the response of MSCs during bone
differentiation from a compromised model.
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In this study, we obtained an OVX rat model, which is considered the gold standard for
studying bone degenerative diseases [9]. This model shares many clinical similarities
with estrogen deficient, postmenopausal bone loss including: (1) increased rate of bone
turnover (2) initial phase of rapid bone loss followed by a much slower decline in bone
loss and (3) greater loss of cancellous than cortical bone [9, 42]. Additionally, the
reduction of bone density post ovariectomy is accelerated by consumption of a low
calcium diet [9, 43, 44]. Using this OVX model, serum biomarkers confirmed greater
bone resorption activity within OVX animals versus control animals (Figure 5.1). This
result was similar to other tested markers previously reported [9, 35, 45]. We then
proceeded to isolate, expand, and characterize MSCs from the bone marrow of both
animal groups. A major criterion of MSCs identity is the positive and negative
expression of specific CD markers. Both con-MSCs and ovx-MSCs demonstrated
positive expression of CD29, CD73, and CD90 and negative expression of CD11b/c and
CD45, the latter associated with the hematopoietic lineage (Figure 5.2).

To examine the osteogenic potential, con-MSCs and ovx-MSCs were exposed to osteochemical inducers using a well-established cocktail of dexamethasone, beta glycerol
phosphate, and ascorbic acid. Under these in vitro conditions, rat and human MSCs
undergo osteogenic differentiation in ~3 weeks [22, 23, 46]. After 21 days, our analysis
confirmed that con-MSCs responded to the bone differentiation cocktail, whereas ovxMSCs did not.

To investigate the genetic differences between these cells, we performed a genomewide expression analyses using RNA sequencing. For the first time, our study
investigates specific gene clusters well established in the bone differentiation process,
including cell adhesion, ECM, growth factors, Wnt-Catenin signaling, MAPK signaling,
mineralization, and bone remodeling [28-33, 47]. Similar gene clusters have been
investigated in other bone differentiation studies [26]. Overall, we observed a consistent
pattern whereby con-MSCs expressed more upregulated genes within most clusters.
However, there were some clusters with no obvious differences between con-MSCs and
ovx-MSCs (i.e. VEGFs, EGFs, AKTs, etc.). This is also important as these targets may
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not be necessary during new drug developments or gene editing strategies. In other
clusters, (i.e. proteoglycans, Wnts, Frizzleds, PI3K, etc.), the total number of
upregulated genes are the same between con-MSCs and ovx-MSCs, but yet the overall
ratio is greater in con-MSCs. For example, the total number of proteoglycans in conMSCs and ovx-MSCs overtime was 10 and 12, respectively, yet both groups had the
same upregulated proteoglycans. Hence, the ratio of upregulated proteoglycans
appears greater in con-MSCs (Figure 5.4B), but specific genes different between these
two groups were not found. It is also possible that since con-MSCs completed
differentiation by Day 21, these cells subsequently advanced to a bone remodeling
cycle, which is evident by several changes in MMPs, the bone remodeling genes
(Figure 5.9) [39, 47]. In other words, once cells have entered bone remodeling, the
proactive goal is bone maintenance rather than bone differentiation.

Hereafter, we named several gene isoforms that did not share commonality between
both MSC sources (Table 4.2). Identifying these genes opens more strategies in
targeting the endogenous MSCs following menopause. For example, current
pharmaceutical strategies commonly target one gene, protein, or pathway to treat bone
degenerative diseases [48, 49]. However, osteogenic differentiation is a complex
system that requires coordination from hundreds to thousands of genes [50]. Many
studies draw conclusions of osteogenesis (or lack thereof) based on single markers (i.e.
RUNX2, ALPL, etc.) via PCR reactions [51-53]. Although these genes are important, the
genome as a whole is necessary to keep the cell functionally active, healthy, and
responsive to differentiation signals. Therefore, PCR is not suitable when studying cell
behavior during a diseased process. As such, examining genome wide expression via
RNA sequencing is a valuable tool to dissect out exactly what genes are affected by this
bone degenerative model.

Several studies have implemented RNA sequencing strategies within the OVX rodent
model to identify novel targets during osteoporosis, sarcopenia, and menopausal
syndrome [54-59]. Chai et al., 2019 identified many long non-coding RNA (IncRNA)
transcripts from the bone and skeletal muscle of OVX rats [54]. Similarly, Gu et al., 2021
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also identified several lncRNAs in the pathogenesis of ovx-MSCs [55]. Supportively,
Teng et.al., 2020 identified lncRNAs from serum exosomes of osteoporotic, human
samples [60]. Finally, mechanistic studies of anti-osteoporotic drugs on ovx-MSCs have
been reported [57]. However, until now no study had established that MSCs from the
OVX model are genetically dysfunctional during new bone development.
It should also be noted that because RNA sequencing produces expression on
thousands of genes, there are challenges on how this data is reported. Traditionally,
RNA sequencing studies report results from bioinformatics databases [61-63]. These
databases interpret results by pooling information from other literature sources which
arbitrarily maps possibly involved pathways, thereby drawing indefinite conclusions. In
other words, without specifically targeting those pathways with chemical inhibitors or
knockdown/knockout experiments, then it is difficult to elucidate the exact mechanisms.
Overall, our data shows that the pathophysiology of MSCs during bone degeneration is
a complex process that is not attributed to one single factor, but rather a combination of
multiple factors which conjunctively delays new bone differentiation. For example,
normal bone development begins with activated MSCs that advances through a series
of stages: proliferation and commitment (osteoprogenitors), differentiation (preosteoblasts), and mineralization (osteoblasts), before finally becoming mature
osteocytes [64]. Each of these stages are governed by various molecules, such as
RUNX2 which commits the MSC into osteoprogenitors and pre-osteoblasts [31, 64].
Similarly, we found RUNX2 upregulation in both con-MSCs and ovx-MSCs, but yet
mineralization content was different between these two groups. Supportively, ALPL,
being a major phosphatase for bone mineralization, was downregulated in ovx-MSCs.
This indicates the ovx-MSCs were functioning as osteoprogenitors, but could not reach
the end goal of mineralization due to lack of other signaling molecules, as presented in
this study (i.e. cadherins, growth factors, MAPKs, MMPs, etc.). The question arises
then, could the genome of geriatric MSCs be engineered to behave “normally” and
ultimately reverse bone degeneration? To answer that question, this study lays the
foundation for identifying genes of MSCs that do not behave normally when cued by
bone differentiation signals. Future experiments to confirm these genetic changes in
animal models are under development.

115

CONCLUSIONS
Understanding the pathophysiology of MSCs during bone degeneration is critical to
developing effective strategies that both improves the human quality of life and relieves
economic healthcare burdens. Since bone degeneration is in part attributed to MSC
senescence, we studied the genetic expressions of MSCs derived from an in vivo bone
degenerative model. Our data found that con-MSCs do have the ability to respond to
bone differentiation, whereas ovx-MSCs do not. Further analysis showed clear genetic
alterations that likely causes MSC senescence, and hence reduced bone formation.
This information is necessary for future medical interventions that could prevent or even
reverse the onset of age-related bone degeneration.

116

REFERENCES
1.
2.
3.

4.

5.
6.
7.

8.

9.

10.

11.
12.
13.

14.

15.

16.
17.

Ryan, J.M., et al., Mesenchymal stem cells avoid allogeneic rejection. J Inflamm
(Lond), 2005. 2: p. 8.
Kariminekoo, S., et al., Implications of mesenchymal stem cells in regenerative
medicine. Artificial cells, nanomedicine, and biotechnology, 2016. 44: p. 1-9.
Pan, Q., et al., Local administration of allogeneic or autologous bone marrowderived mesenchymal stromal cells enhances bone formation similarly in
distraction osteogenesis. Cytotherapy, 2021. 23(7): p. 590-598.
Wang, Q., et al., Decreased proliferation ability and differentiation potential of
mesenchymal stem cells of osteoporosis rat. Asian Pac J Trop Med, 2014. 7(5):
p. 358-63.
Chen, H., et al., Aging and Mesenchymal Stem Cells: Therapeutic Opportunities
and Challenges in the Older Group. Gerontology, 2021.
Thompson, D.D., et al., FDA Guidelines and animal models for osteoporosis.
Bone, 1995. 17(4 Suppl): p. 125s-133s.
Johnston, B.D. and W.E. Ward, The ovariectomized rat as a model for studying
alveolar bone loss in postmenopausal women. BioMed research international,
2015. 2015: p. 635023-635023.
Ren, W., et al., CHANGES OF WNT/B-CATENIN SIGNALING AND
DIFFERENTIATION POTENTIAL OF BONE MARROW MESENCHYMAL STEM
CELLS IN PROCESS OF BONE LOSS IN OVARIECTOMIZED RATS. Acta
Endocrinol (Buchar), 2020. 16(2): p. 156-164.
Gao, X., et al., Establishing a rapid animal model of osteoporosis with
ovariectomy plus low calcium diet in rats. Int J Clin Exp Pathol, 2014. 7(8): p.
5123-8.
Boeloni, J.N., et al., Comparative study of osteogenic differentiation potential of
mesenchymal stem cells derived from bone marrow and adipose tissue of
osteoporotic female rats. Connect Tissue Res, 2014. 55(2): p. 103-14.
Wang, Z., M. Gerstein, and M. Snyder, RNA-Seq: a revolutionary tool for
transcriptomics. Nature reviews. Genetics, 2009. 10(1): p. 57-63.
Kukurba, K.R. and S.B. Montgomery, RNA Sequencing and Analysis. Cold
Spring Harb Protoc, 2015. 2015(11): p. 951-69.
Eastell, R. and R.A. Hannon, CHAPTER 27 - Biochemical Markers of Bone
Turnover, in Treatment of the Postmenopausal Woman (Third Edition), R.A.
Lobo, Editor. 2007, Academic Press: St. Louis. p. 337-349.
Lv, Y., et al., Tartrate-resistant acid phosphatase 5b is a marker of osteoclast
number and volume in RAW 264.7 cells treated with receptor-activated nuclear
κB ligand. Experimental and therapeutic medicine, 2015. 9(1): p. 143-146.
Kuo, T.-R. and C.-H. Chen, Bone biomarker for the clinical assessment of
osteoporosis: recent developments and future perspectives. Biomarker
Research, 2017. 5(1): p. 18.
Zou, W., et al., Congenital lipodystrophy induces severe osteosclerosis. PLoS
Genet, 2019. 15(6): p. e1008244.
Abdelmagid, S.M., et al., Mutation in Osteoactivin Promotes Receptor Activator
of NFkappaB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival
but Inhibits Osteoclast Function. J Biol Chem, 2015. 290(33): p. 20128-46.

117
18.
19.
20.

21.

22.

23.
24.

25.

26.

27.
28.

29.
30.

31.
32.
33.

34.

Raghuvanshi, P.D., Mesenchymal Stem Cells Derived from Rat Bone Marrow
(rBM MSC): Techniques for Isolation, Expansion and Differentiation. 2018.
Fafián-Labora, J., et al., Influence of age on rat bone-marrow mesenchymal stem
cells potential. Scientific Reports, 2015. 5(1): p. 16765.
Alghazali, K., et al., Functionalized gold nanorod nanocomposite system to
modulate differentiation of human mesenchymal stem cells into neural-like
progenitors. Scientific Reports, 2017. 7.
Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal
cells. The International Society for Cellular Therapy position statement.
Cytotherapy, 2006. 8(4): p. 315-7.
Lee, D.J., et al., Osteogenic potential of mesenchymal stem cells from rat
mandible to regenerate critical sized calvarial defect. Journal of tissue
engineering, 2019. 10: p. 2041731419830427-2041731419830427.
Kaur, G., et al., Regulation of osteogenic differentiation of rat bone marrow
stromal cells on 2D nanorod substrates. Biomaterials, 2010. 31(7): p. 1732-1741.
Elkhenany, H., et al., Impact of the source and serial passaging of goat
mesenchymal stem cells on osteogenic differentiation potential: implications for
bone tissue engineering. Journal of Animal Science and Biotechnology, 2016.
7(1): p. 16.
Newby, S.D., et al., Functionalized Graphene Nanoparticles Induce Human
Mesenchymal Stem Cells to Express Distinct Extracellular Matrix Proteins
Mediating Osteogenesis. International journal of nanomedicine, 2020. 15: p.
2501-2513.
MacDonald, A., et al., Genetic profiling of human bone marrow and adipose
tissue-derived mesenchymal stem cells reveals differences in osteogenic
signaling mediated by graphene. Journal of Nanobiotechnology, 2021. 19.
Mueller, O., S. Lightfoot, and A. Schroeder, RNA integrity number (RIN)standardization of RNA quality control. Agilent Application Note, 2004: p. 1-8.
Marie, P.J., E. Haÿ, and Z. Saidak, Integrin and cadherin signaling in bone: role
and potential therapeutic targets. Trends Endocrinol Metab, 2014. 25(11): p. 56775.
Lin, X., et al., The Bone Extracellular Matrix in Bone Formation and
Regeneration. Frontiers in Pharmacology, 2020. 11.
Zhang, L. and H. Ai, Concentrated growth factor promotes proliferation,
osteogenic differentiation, and angiogenic potential of rabbit periosteum-derived
cells in vitro. Journal of Orthopaedic Surgery and Research, 2019. 14(1): p. 146.
Rutkovskiy, A., K.-O. Stensløkken, and I.J. Vaage, Osteoblast Differentiation at a
Glance. Medical science monitor basic research, 2016. 22: p. 95-106.
Zayzafoon, M., Calcium/calmodulin signaling controls osteoblast growth and
differentiation. J Cell Biochem, 2006. 97(1): p. 56-70.
Prins, H.-J., et al., In vitro induction of alkaline phosphatase levels predicts in
vivo bone forming capacity of human bone marrow stromal cells. Stem Cell
Research, 2014. 12(2): p. 428-440.
Paiva, K. and J. Granjeiro, Matrix Metalloproteinases in Bone Resorption,
Remodeling, and Repair. 2017. p. 203-303.

118
35.

36.

37.

38.
39.

40.

41.
42.
43.

44.

45.

46.

47.
48.
49.

50.

Tsai, Y.-F., et al., Long-Term Oral Toxicity and Anti-osteoporotic Effect of
Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal
Osteoporosis. Journal of medical and biological engineering, 2017. 37(2): p. 181190.
Newby, S.D., et al., Functionalized Graphene Nanoparticles Induce Human
Mesenchymal Stem Cells to Express Distinct Extracellular Matrix Proteins
Mediating Osteogenesis. Int J Nanomedicine, 2020. 15: p. 2501-2513.
Di Benedetto, A., et al., Osteogenic differentiation of mesenchymal stem cells
from dental bud: Role of integrins and cadherins. Stem Cell Research, 2015.
15(3): p. 618-628.
Klezovitch, O. and V. Vasioukhin, Cadherin signaling: keeping cells in touch.
F1000Research, 2015. 4(F1000 Faculty Rev): p. 550-550.
Liang, H., et al., Matrix metalloproteinases in bone development and pathology:
current knowledge and potential clinical utility. Metalloproteinases In Medicine,
2016. Volume 3: p. 93-102.
Zupan, J., et al., Age-related alterations and senescence of mesenchymal
stromal cells: Implications for regenerative treatments of bones and joints.
Mechanisms of Ageing and Development, 2021. 198: p. 111539.
Feng, X. and J.M. McDonald, Disorders of bone remodeling. Annual review of
pathology, 2011. 6: p. 121-145.
Kalu, D.N., The ovariectomized rat model of postmenopausal bone loss. Bone
Miner, 1991. 15(3): p. 175-91.
Mao, H., et al., Metabolomics and physiological analysis of the effect of calcium
supplements on reducing bone loss in ovariectomized rats by increasing estradiol
levels. Nutrition & Metabolism, 2021. 18(1): p. 76.
Lee, M.-R., et al., Effects of a Low Calcium Diet and Oxalate Intake on Calcium
Deposits in Soft Tissues and Bone Metabolism in Ovariectomized Rats. kjn,
2011. 44(2): p. 101-111.
Hsiao, C.-Y., et al., Calcitonin Induces Bone Formation by Increasing Expression
of Wnt10b in Osteoclasts in Ovariectomy-Induced Osteoporotic Rats. Frontiers in
Endocrinology, 2020. 11.
Hu, H., et al., An Inhibitory Role of Osthole in Rat MSCs Osteogenic
Differentiation and Proliferation via Wnt/β-Catenin and Erk1/2-MAPK Pathways.
Cellular Physiology and Biochemistry, 2016. 38(6): p. 2375-2388.
Paiva, K.B.S. and J.M. Granjeiro, Matrix Metalloproteinases in Bone Resorption,
Remodeling, and Repair. Prog Mol Biol Transl Sci, 2017. 148: p. 203-303.
Drake, M.T., B.L. Clarke, and S. Khosla, Bisphosphonates: mechanism of action
and role in clinical practice. Mayo Clinic proceedings, 2008. 83(9): p. 1032-1045.
Casas, A.I., et al., From single drug targets to synergistic network pharmacology
in ischemic stroke. Proceedings of the National Academy of Sciences, 2019.
116(14): p. 7129.
Cohen-Zinder, M., D. Karasik, and I. Onn, Structural maintenance of
chromosome complexes and bone development: the beginning of a wonderful
relationship? BoneKEy reports, 2013. 2: p. 388-388.

119
51.

52.

53.

54.

55.

56.

57.

58.

59.
60.

61.

62.

63.
64.

Frank, O., et al., Real-time quantitative RT-PCR analysis of human bone marrow
stromal cells during osteogenic differentiation in vitro. J Cell Biochem, 2002.
85(4): p. 737-46.
Okamura, K., et al., RT-qPCR analyses on the osteogenic differentiation from
human iPS cells: an investigation of reference genes. Scientific Reports, 2020.
10(1): p. 11748.
Pettersson, L.F., et al., In Vitro Osteogenic Differentiation of Human
Mesenchymal Stem Cells from Jawbone Compared with Dental Tissue. Tissue
Engineering and Regenerative Medicine, 2017. 14(6): p. 763-774.
Chai, S., et al., Systematic analysis of long non-coding RNA and mRNA profiling
using RNA sequencing in the femur and muscle of ovariectomized rats. Journal
of musculoskeletal & neuronal interactions, 2019. 19(4): p. 422-434.
Gu, H., et al., Expression Profile Analysis of Long Non-coding RNA in OVX
Models-Derived BMSCs for Postmenopausal Osteoporosis by RNA Sequencing
and Bioinformatics. Frontiers in Cell and Developmental Biology, 2021. 9.
Wang, W., et al., Transcriptomic changes in the hypothalamus of ovariectomized
mice: Data from RNA-seq analysis. Annals of Anatomy - Anatomischer Anzeiger,
2022: p. 151886.
Guo, X., et al., RNA-Seq investigation and in vivo study the effect of strontium
ranelate on ovariectomized rat via the involvement of ROCK1. Artificial Cells,
Nanomedicine, and Biotechnology, 2018. 46(sup1): p. 629-641.
Kanaya, N., et al., Single-cell RNA-sequencing analysis of estrogen- and
endocrine-disrupting chemical-induced reorganization of mouse mammary gland.
Communications Biology, 2019. 2(1): p. 406.
Iqbal, J., et al., Estradiol Alters Hippocampal Gene Expression during the Estrous
Cycle. Endocr Res, 2020. 45(2): p. 84-101.
Teng, Z., et al., Osteoporosis Is Characterized by Altered Expression of
Exosomal Long Non-coding RNAs. Frontiers in genetics, 2020. 11: p. 566959566959.
Kang, W., et al., Transcriptome analysis reveals the mechanism of stromal cellderived factor-1 and exendin-4 synergistically promoted periodontal ligament
stem cells osteogenic differentiation. PeerJ, 2021. 9: p. e12091.
Zhao, Z., et al., Radial extracorporeal shockwave promotes subchondral bone
stem/progenitor cell self-renewal by activating YAP/TAZ and facilitates cartilage
repair in vivo. Stem Cell Research & Therapy, 2021. 12(1): p. 19.
Shaik, S., et al., Transcriptomic Profiling of Adipose Derived Stem Cells
Undergoing Osteogenesis by RNA-Seq. Scientific Reports, 2019. 9(1): p. 11800.
Javed, A., H. Chen, and F.Y. Ghori, Genetic and transcriptional control of bone
formation. Oral and maxillofacial surgery clinics of North America, 2010. 22(3): p.
283-v.

120

APPENDIX

A.

Average Animal Weight (g)
500

*
400
300
200
100
0

Control

B.
140

OVX

Average Osteoclast Activity
*

CTX-1 / TRAP5b

120
100
80
60
40
20
0

Control

OVX

Figure 4.1. (A) Final weight of control and ovariectomized animals on the day of
sacrifice. (B) The ratio of C-telopeptide of type I collagen (CTX-1) to tartrate-resistant
acid phosphate isoform 5b (TRAP5B) in serum protein collected from animals on the day
of sacrifice; n = 6; asterisk indicates statistical significance; error bars presented as
SEM.
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Figure 4.2. Expression of MSC Markers. Flow cytometry analysis showed that all MSC
sources positively expressed positive markers (CD29, CD73, CD90) and negatively
expressed negative markers (CD11b/c and CD45).
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Figure 4.3. Osteogenic Differentiation Assay. (A) Calcium content of control and OVX
derived MSCs cultured in either undifferentiated (inset) or osteogenic differentiation media for
21 days. Images were taken at 10X magnification. (B) Quantification of alizarin red staining of
cells exposed to osteogenic induction media for 21 days; n=3, error bars presented as SEM.
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Table 4.1. RNA sequencing analysis of common bone differentiation markers. For each group,
MSCs cultured in osteo-differentiation media for 7 days was set as the control, while cells cultured for
21 days was set as the tested group. The p-adjusted value was set to 0.05 with a log2 fold change of a
positive (+) or negative (-) value indicating upregulation and downregulation, respectively. NC = No
Change.

CON-MSCs

OVX-MSCs

Gene Name

log2FoldChange

log2FoldChange

Dlx5

NC

NC

Runx2

+

+

Sox9

NC

NC

Sp7

NC

NC

Alpl

NC

-

Spp1

+

+
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Figure 4.4. The percentage of upregulated genes related to adhesion, extracellular
matrix, and growth factors. For each group, MSCs cultured in osteo-differentiation media for
7 days were set as the control, while cells cultured for 21 days was set as the tested group. (A)
The percentage of upregulated integrin and cadherin genes within MSCs derived from both
control and OVX animals. (B) The percentage of upregulated ECM genes within MSCs derived
from both control and OVX animals. (C) The percentage of upregulated growth factors and (D)
sex hormones
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Figure 4.4. Continued.
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Figure 4.5. The percentage of upregulated genes related to Wnt/β-Catenin
signaling. For each group, MSCs cultured in osteo-differentiation media for 7 days were
set as the control, while cells cultured for 21 days was set as the tested group.
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Figure 4.6. The percentage of upregulated genes related to cell signaling/differentiation.
For each group, MSCs cultured in osteo-differentiation media for 7 days were set as the control,
while cells cultured for 21 days was set as the tested group.
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Figure 4.7. The percentage of upregulated genes related to mineralization. For each group, MSCs
cultured in osteo-differentiation media for 7 days were set as the control, while cells cultured for 21 days was
set as the tested group. The percentage of upregulated genes involving calcium or phosphatases within MSCs
derived from both control and OVX animals.
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Figure 4.8. The percentage of upregulated metallopeptidase (bone remodeling) genes. For each
group, MSCs cultured in osteo-differentiation media for 7 days were set as the control, while cells
cultured for 21 days was set as the tested group.
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Table 4.2. List of specific genes upregulated in con-MSCs, but not in ovx-MSCs. For each
group, MSCs cultured in osteo-differentiation media for 7 days were set as the control, while cells
cultured for 21 days was set as the tested group. + indicates upregulation; NC = No Change.

Gene Description

Symbol

log2
Fold
Change
(ConMSCs)

log2
Fold
Change
(OVXMSCs)

Itfg1

+

NC

AC103179.2
Cdh6
Ctnnd2
Pcdh18
Pcdh7
Pcdhac1
Pcdhga10
Pcdhga2
Pcdhga7

+
+
+
+
+
+
+
+
+

NC
NC
NC
NC
NC
NC
NC
NC
NC

Col4a3bp

+

Col4a6

+

NC

Sv2b

+

NC

Rerg
Gper1
Bcar3

+
+
+

NC
NC
NC

Parm1

+

-

Adhesion
Integrins
integrin alpha FG-GAP repeat containing 1
Cadherins
Protocadherin alpha-4
cadherin 6, type 2, K-cadherin
catenin (cadherin-associated protein), delta 2
protocadherin 18
protocadherin 7
protocadherin alpha subfamily C, 1
protocadherin gamma subfamily A, 10
protocadherin gamma subfamily A, 2
protocadherin gamma subfamily A, 7
ECM
Collagens
collagen, type IV, alpha 3 (Goodpasture antigen) binding
protein
collagen, type IV, alpha 6
Glycoproteins
synaptic vesicle glycoprotein 2b
Estrogens
RAS-like, estrogen-regulated, growth-inhibitor
G protein-coupled estrogen receptor 1
breast cancer anti-estrogen resistance 3
Androgens
prostate androgen-regulated mucin-like protein 1

NC
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Table 4.2. Continued.

Gene Description

Symbol

Log2
Fold
Change
(ConMSCs)

Log2
Fold
Change
(OVXMSCs)

Bmpr1b

+

NC

Ltbp4

+

NC

Fgfr1
Fgfr1op2
Fgfr3

+
+
+

NC
NC
NC

Pdgfc
Pdgfd

+
+

NC
NC

Igfbp5
Insig2

+
+

NC
NC

Ctnnd2

+

NC

Smad1

+

NC

Mapk1ip1l
Mapk8
Mapk9

+
+
+

NC
NC
NC

Growth Factors
BMPs
bone morphogenetic protein receptor, type IB
TGFs
latent transforming growth factor beta binding protein 4
FGFs
Fibroblast growth factor receptor 1
FGFR1 oncogene partner 2
fibroblast growth factor receptor 3
PDGFs
platelet derived growth factor C
platelet derived growth factor D
IGFs
insulin-like growth factor binding protein 5
insulin induced gene 2
Wnt / Catenin Signaling
Catenins
catenin (cadherin-associated protein), delta 2
SMADs
SMAD family member 1
Cell Signaling
MAPK
mitogen-activated protein kinase 1 interacting protein 1-like
mitogen-activated protein kinase 8
mitogen-activated protein kinase 9
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Table 4.2. Continued.

Gene Description

Symbol

Log2
Fold
Change
(ConMSCs)

Log2
Fold
Change
(OVXMSCs)

C2cd2
C2cd3
Camk1d
Mcu
Mcur1
Micu1
Ppef1
Smoc1

+
+
+
+
+
+
+
+

NC
NC
NC
NC
NC
NC
NC
NC

Dusp16
Dusp18
Dusp8
Enpp2
Eya1
Inpp4b
Ppef1
Ppm1b
Ppm1f
Ppm1k
Ppm1l

+
+
+
+
+
+
+
+
+
+
+
+

NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC
NC

Ppp1r13b
Ppp1r2
Ppp1r3c
Ppp1r3d
Ppp3ca
Ppp3r1
Pptc7
Ptpn4
Ptpra
Ptprm

+
+
+
+
+
+
+
+
+
+

NC
NC
NC
NC
NC
NC
NC
NC
NC
NC

Mmp12
Mmp13
Mmp16
Mmp2
Mmp9

+
+
+
+
+

NC
NC
NC
NC
NC

Mineralization
Calcium
C2 calcium-dependent domain containing 2
C2 calcium-dependent domain containing 3
calcium/calmodulin-dependent protein kinase ID
mitochondrial calcium uniporter
mitochondrial calcium uniporter regulator 1
mitochondrial calcium uptake 1
protein phosphatase, EF-hand calcium binding domain 1
SPARC related modular calcium binding 1
Phosphatases
dual specificity phosphatase 16
dual specificity phosphatase 18
dual specificity phosphatase 8
ectonucleotide pyrophosphatase/phosphodiesterase 2
EYA transcriptional coactivator and phosphatase 1
inositol polyphosphate-4-phosphatase, type II
protein phosphatase, EF-hand calcium binding domain 1
protein phosphatase, Mg2+/Mn2+ dependent, 1B
protein phosphatase, Mg2+/Mn2+ dependent, 1F
protein phosphatase, Mg2+/Mn2+ dependent, 1K
protein phosphatase, Mg2+/Mn2+ dependent, 1L
Protein Ppp1r12b; Protein phosphatase 1, regulatory
(Inhibitor) subunit 12B (Predicted)
protein phosphatase 1, regulatory subunit 13B
protein phosphatase 1, regulatory (inhibitor) subunit 2
protein phosphatase 1, regulatory subunit 3C
protein phosphatase 1, regulatory subunit 3D
protein phosphatase 3, catalytic subunit, alpha isozyme
protein phosphatase 3, regulatory subunit B, alpha
PTC7 protein phosphatase homolog (S. cerevisiae)
protein tyrosine phosphatase, non-receptor type 4
protein tyrosine phosphatase, receptor type, A
protein tyrosine phosphatase, receptor type, M
Bone Remodeling
MMPs
matrix metallopeptidase 12
matrix metallopeptidase 13
matrix metallopeptidase 16
matrix metallopeptidase 2
matrix metallopeptidase 9

Ppp1r12b
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CHAPTER V:
3D-PRINTED RGO CONSTRUCTS SUPPORT MANDIBULAR DEFECTS
IN AN OSTEOPOROTIC RODENT MODEL
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ABSTRACT
Mandibular bone degeneration is a rising concern for post-menopause osteoporotic
women, thereby increasing the risk of traumatic jaw injuries. The current standard for
repairing mandible defects are autologous bone grafts, but this strategy creates a
second morbidity site and increases the risk of infection. Alternatively, the field of tissue
engineering is actively investigating the use of stem cells and 3D biomaterials to
stimulate new bone for mandible injuries. Reduced graphene oxide (rGO), is a carbonbased material that spontaneously supports bone differentiation of adult mesenchymal
stem cells (MSCs). However, rGO-MSC constructs have not been tested in in vivo
mandible defects. To mimic post-menopause osteoporosis, we began this study with the
ovariectomized (OVX) rodent model and created critical-sized mandible defects. These
defects were filled with 3D-printed rGO-MSC constructs and treated for 60 days. MicroCT and histology analysis demonstrated that the rGO-MSC constructs supported new
bone regeneration of mandibular defects in both normal adult rats and osteoporotic rats,
and hence is a potential strategy for reconstructing traumatic jaw injuries. To our
knowledge, this is one of the first studies to (1) examine a bone regenerative treatment
of osteoporotic mandibles and (2) to test rGO scaffolds in maxillofacial bones. In the
future, long-term studies are needed to determine the maximum bone differentiation
potential of rGO scaffolds, and whether this process should be enhanced with other
biological components.
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INTRODUCTION
Mandibular bone degeneration is a rising concern for post-menopause osteoporotic
women, thereby increasing susceptibility of traumatic jaw fractures [1, 2]. Currently, jaw
reconstruction is treated with autologous bone grafts, but this strategy is infeasible for
patients with bone degenerative diseases [3]. Additionally, anti-osteoporotic medications
such as bisphosphonates have harmful side effects, are too expensive, and are linked
to osteonecrosis of the jaw [4-6].
The alternative strategy for treating mandibular defects is regenerative medicine,
whereby the primary goal is to rebuild functional tissues with stem cells and threedimensional (3D) biomaterials. Graphene, an allotrope of carbon, is a proposed bone
biomaterial, due to its very strong, yet lightweight and flexible properties. Additionally,
graphene supports traumatic bone defects, demonstrates cell compatibility, and
spontaneously stimulates bone differentiation of adult mesenchymal stem cells (MSCs)
[7, 8]. However, it is unclear if graphene materials can similarly regenerate new tissue
within a diseased, bone degenerative model. Therefore, we overall investigated if
graphene scaffolds would be an ideal candidate for (1) supporting mandible defects and
(2) supporting new bone development within an osteoporotic model.
In this study, we successfully 3D printed reduced graphene oxide (rGO) scaffolds,
specifically tailored for mandibular deformities. Subsequently, these scaffolds were
implanted into mandible defects of the ovariectomized (OVX) rodent model, which
mimics post-menopause osteoporosis [9, 10]. We hypothesized that rGO scaffolds
would support mandibular bone development in both normal and osteoporotic rats.

METHODS
Cell Isolation and Culture
Patient consent for collecting adipose tissue following a panniculectomy was obtained
and approved by an IRB protocol at the University of Tennessee Medical Center in
Knoxville. Human adipose-derived mesenchymal stem cells (AD-MSCs) were isolated
and characterized as previously described [7, 11]. AD-MSCs were cultured in DMEM-
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F12 media, supplemented with 10% FBS, 1% penicillin, and 1% streptomycin and
maintained in an atmosphere of 5% CO2 at 37°C.
Scaffold Design and Preparation
The scaffold design (as previously described by Newby et al., unpublished) was
constructed in computer-aided design (CAD) software (Autodesk Fusion 360), whereby
the scaffold pattern was a 5 mm diameter circle, composed of 15 layers. Additionally,
the scaffold was designed to achieve ~80% porosity, whereby the gap size between
printed lines was 100-300 µm to support osteogenic potential [12]. The final design was
then digitally formatted into a Standard Tessellation Language (STL) file format and
loaded into the Element slicing software. The slicing software ‘slices’ the design into
values that denote how each layer is to be printed, overall developing a control
language known as a G-code file. These files were then exported to the Cellink-BIO
X6™ printer.
Prior to printing, rGO (Cheap Tubes Inc., Grafton, VT), was mixed into poly(lactic-coglycolic) acid (PLGA), being 65% lactic acid and 35% glycolic acid (Sigma-Aldrich, St.
Louis, MO) and 0.5 mL DMSO, for a final concentration of 0.5% rGO. The mixture was
then melted at 85°C for ~2 hr. or until homogeneous, followed by overnight storage in 20°C. The rGO-PLGA material was then loaded into a syringe connected to the CellinkBIO X6™ printer. Each scaffold was printed at 5 (L) X 5 (W) X 2 (H) mm. Printing
parameters (i.e. extruder temperature, print bed temperature, speed, and pressure)
were manually set and adjusted as necessary.
DiI Staining
To identify cell attachment to the rGO scaffold, we stained AD-MSCs with
CellTracker™-Dil Dye (Invitrogen molecular probes, #C7001). DiI Dye is a fluorescent
stain with a red excitation/emission spectra of 553/570 nm maxima. It freely passes
through the cell membrane and subsequently transforms into cell-impermeant reaction
products. Briefly, AD-MSCs were split in 0.5% trypsin, then centrifuged before washing
with 1X HBSS. The Dil Dye solution was added to the cell pellet at a total volume of 1
mL and incubated at 37°C for 15 min before washing and resuspending in media. To
direct cell attachment, scaffolds were placed inside a collection tube and AD-MSCs
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were seeded at 1 X 106. The rGO-cell construct was incubated for 48 hr and then fixed
in 4% paraformaldehyde prior to imaging (Leica SP8 confocal microscope).
Animal Model
All procedures were approved by the University of Tennessee Institutional Animal Care
and Use Committee. 12 female Sprague Dawley rats were purchased from Charles
River (Wilmington, MA) that underwent either a bilateral ovariectomy (n=6) or were
sham-operated (n=6) to mimic surgical stress between both groups. The animals (at 9
weeks old) arrived to the University of Tennessee Veterinary Medical Center, were
housed in pairs, and acclimatized for one week. Following acclimatization, animals were
housed individually to control for diet consumption.
Rats were fed a commercially available low calcium diet (Envigo,Indianapolis, ID), as
previously described (MacDonald et al., in review). The formula consisted of casein
(200 g/Kg), L-cystine (3.0 g/Kg), sucrose (342.188 g/Kg), corn starch (320.0 g/Kg),
soybean oil (60 g/Kg), cellulose (40 g/Kg), mineral mix (Ca-P deficient) (13.37 g/Kg),
potassium phosphate (monobasic) (11.43 g/Kg), vitamin mix (10.0 g/Kg), and
ethoxyquin, an antioxidant (0.012 g/Kg). The casein contributed ~0.01% calcium or less.
The diet also contained ~0.4% phosphorus and 2200 IU vitamin D/Kg diet. Food was
stored at 4°C and used within 6 months of purchasing. Each rat was fed 210 g (+/- 5 g)
of diet every 7 days according to manufacturer recommendations. The rats consumed
this diet for 10 weeks, with food intake and body weights recorded weekly. A separate
group of sham-operated animals (n = 5) were not fed a low calcium diet, but rather a
standard chow diet for 10 weeks.
Surgical Procedure
Prior to surgery, rGO scaffolds were UV sterilized at least 2 hours before seeding ADMSCs at 5 X 105 and incubating overnight at 37°C, 5% CO2.
Animals were anesthetized under isoflurane, the fur was removed, and skin was
cleaned with ethanol and chlorhexidine prior to incision. A linear incision was made
through the skin, subcutaneous tissues, and masseter muscle paralleling the inferior
border of the mandible. The buccal and lingual surfaces of the mandible were exposed
with an elevator, and a 5-mm full-thickness circular defect was drilled in the mandibular
angle (right-side), posterior to the root of the incisor. This ostectomy was performed
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using a high-speed Dremel with a trephine bur and did not interrupt mandibular
continuity at the alveolus. The defect was immediately filled with a rGO-cell construct
and the muscle/skin incisions were sutured (4-0). Buprenorphine was administered presurgery and twice daily for 3 days post-surgery at 0.05 mg/kg. All animals received
water supplemented with Gatorade and Baytril® for one week. A cube of soft-food (BioServe, Flemington, NJ, #S5769) was refreshed daily for 6 weeks before switching to a
standard chow diet. All mandibular defects were treated with the rGO-cell construct for
60 days before sacrificing for further analysis.
Micro-CT
Bilateral mandibles were imaged using a micro-CT specimen scanner (μCT 35, Scanco
Medical; Bassersdorf, Switzerland). Scan parameters were 55 kVp, 145 μA, 400 msec
exposure time, average of 3 exposures per projection, 0.5 mm aluminum filter, 1000
projections per 180 degrees and a 15-micron voxel size. A circle ROI of 6 mm diameter
and 3 mm length was selected for both the defected area and the contralateral (nondefected) side. A region of trabecular bone (ROI = 1.2 mm in length) was taken rostralto-caudal in the mandible, ventral to the incisor’s root, on the contralateral (nondefected) side only. The raw images were calibrated using a hydroxyapatite (HA)
phantom of varying HA concentrations. Noise in the images was reduced by use of a
low-pass Gaussian filter. A threshold of 380 to 3000 mgHA/mm was used to partition
mineralized tissue from other less-dense tissues (low threshold is to exclude soft-tissue
and void space, high threshold is the highest value in the scan). The bone volume
fraction (BV/TV) was determined by dividing the number of voxels (denser than the
threshold) representing mineralized tissue (BV: bone volume) by the total number of
voxels in the region (TV: total volume). The mean density of all material in the volume
is apparent bone mineral density (aBMD). The mean density of only the mineralized
material is the tissue bone mineral density (tBMD). Trabecular number, mean
trabecular thickness, and mean trabecular separation were calculated using a direct
morphometric analysis [13, 14]. Connectivity density was calculated by dividing the
connectivity measure by TV, where connectivity is the maximum number of trabeculae
that can be broken before the specimen is separated into two parts [15].
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Histology
Mandible samples were sent to Ratliff Histology Consultants, LLC and embedded in
undecalcified methylmethacrylate (MMA). Samples were stained and counterstained
with Von kossa and MacNeal’s tetrachrome, respectively. The Von kossa stain was
used to visualize any new mineralized tissue, while MacNeal’s tetrachrome
distinguished the unmineralized tissue. These stains were completed on the defected
mandibles of both sham and OVX rats.

STATISTICS
The average food consumption, body weight, and micro-CT results were analyzed by
the 2-Tailed Student’s T-test and presented as standard error of the mean. Data with an
adjusted P value < 0.05 was considered statistically significant. To determine new bone
regeneration, the BV/TV of the defect relative to the BV/TV of the contralateral side was
quantitated and reported as a percentage.

RESULTS
rGO scaffolds support AD-MSC attachment
rGO scaffolds were successfully constructed via the Cellink Biox6 3D printer (Figure
5.1A-D). Each scaffold was produced in ~7 minutes, with dimensions of 5 (L) X 5 (W) X
2 (H) mm, and a highly porous structure (Figure 5.1E/F). To determine cell attachment,
we stained AD-MSCs with DiI before seeding onto the rGO scaffold. Confocal imaging
revealed the scaffold was confluent with AD-MSCs (Figure 5.1G/H). Overall, this data
shows that rGO can (1) be 3D printed for scaffold construction and (2) support cell
attachment.
OVX animals have higher body weights than control animals
Pre-surgery, both sham and OVX animals were placed on a low calcium diet for 10
weeks. Within the first four weeks, OVX animals consumed more food than sham
animals (Figure 5.3A). However, there were no differences in diet consumption from
weeks 5 – 10.
Post-surgery, both sham and OVX animals were placed on a soft food diet. However,
we noticed that both animal groups stopped consuming the soft food after 6 weeks. We
therefore supplemented a standard chow diet, and weight was either gained or
maintained in the subsequent weeks.
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On the day of surgery and sacrifice, the average body weight of OVX rats was
significantly higher (403 g and 414 g, respectively) than the sham group (313 g and 318
g, respectively) (Figure 5.3B), which is consistent with previous reports [16,
17](MacDonald et al., in review). We also previously established that the average
osteoclast activity (CTX-1:TRAP5b) was greater in OVX animals, thereby confirming
bone resorption activity within OVX animals (MacDonald et al., in review).
Low calcium diet has no effect on mandibular bone density or structure of shamoperated animals
We first examined if there were any differences in mandibular bone density or trabecular
bone architecture of sham animals that were placed on either a standard chow diet
(n=5) or a low calcium diet (n=6). Micro-CT data revealed there were no changes in any
of the parameters tested (BV/TV, aBMD, tBMD, Tb.N, Tb.Th, Tb.Sp, and connective
density) (Table 5.1). Overall, this data is consistent with previous reports that the low
calcium diet does not affect bone density or microarchitecture of sham-operated
animals [18].
Micro-CT reveals changes in mandibular bone density and structure of OVX
animals
We next tested if sham and OVX animals had any changes in mandibular bone density
or structure of the control (non-defect) side only. Micro-CT analysis revealed that the
control mandibles of OVX animals had less BV/TV, aBMD, TB.N, TB.Th, and more
Tb.Sp (Table 5.2). Overall, this data shows that post-menopause bone degeneration
does occur in the mandible and is not limited to common weight-bearing regions such
as the hip or spine.
rGO-cell constructs support new bone material in both sham and OVX animals
Bone regenerated in all mandible defects, with mean percentages of 32% and 39% for
respectively sham and OVX animals, as measured by micro-CT after 60 days (Figure
5.4). Additionally, there was no statistical difference in the BV/TV or aBMD after
comparing the average defect-side: nondefect-side between sham and OVX animals
(Table 5.3). Finally, no osteonecrosis was observed around the ring of the defect. This
suggests that the rGO-cell construct (1) supports new bone regeneration of mandibular
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injuries and (2) is not limited by disease status. However, we were unable to conclude if
the new mineralization was due to the addition of rGO, AD-MSCs, or both.
To further validate the micro-CT analysis, in vivo results of histological von Kossa and
MacNeal’s tetrachrome staining highlighted calcium deposits and collagen formation,
respectively (Figure 5.5). There was noticeably a cartilage outline within the defect site,
suggesting that cells were supported by a porous scaffold structure. Additionally, the
area between existing bone and the defect showed cell integration, suggesting cell
migration to the construct. However, it should be noted that some rGO particles are
mixed within mineralization sites, and therefore it is difficult to accurately quantitate new
bone formation. We therefore examined Masson’s Trichrome staining and did observe
faint green areas within the defect site of both sham and OVX animals (Figure 5.6). This
suggested the presence of osteoprogenitors, but are not yet mature osteocytes.
Overall, these data suggests that the rGO-cell construct supported mandibular bone
regeneration of a critical-sized defect in both sham and OVX animals.

DISCUSSION
The mandible is one of the most proactive bones of the body, vital for eating, talking,
and swallowing. Therefore, any traumatic injury of the mandible could be debilitating.
The current standard for mandible reconstruction is autologous bone grafts, commonly
derived from the fibula [19, 20]. However, this strategy imposes a donor site morbidity,
increases the risk of infection, and further yet is infeasible for individuals already
undergoing chronic bone degeneration. The alternative, yet undeveloped strategy is
regenerative medicine, which focuses on engineering new tissues with 3D-biological
materials and stem cell therapies. But alarmingly, in vivo studies of mandibular bone
regeneration are limited, leaving few treatment strategies for maxillofacial surgeons.
To study mandibular bone regeneration, we obtained the OVX rat model, which is well
established in mimicking post-menopause osteoporosis [9]. However, there are
questions surrounding the effects of estrogen deficiency on mandibular bone density. In
other words, does post-menopause osteoporosis systematically effect all bones, or
does it only effect common weight-bearing regions (i.e., femur, spine, etc.). Miyake et
al., 1995 reported that a patient diagnosed with a severe case of post-menopause
osteoporosis had defects of both mandibular condyles [21]. Other studies indicate that
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osteoporosis of the mandible represents an advanced stage, whereby the disease is
preceded in the femur [22]. Further yet, specific anatomical regions of the mandible are
more sensitive to osteolytic changes than others [22, 23]. For example, alveolar bone
deteriorates more quickly than the mandibular body or condyle [22]. Overall, different
laboratories have identified that post-menopause bone degeneration is not limited to
weight bearing regions and does affect maxillofacial bones [24-27].
In this study, we established that mandibles of OVX rats had reduced bone density and
microarchitectural changes, confirming mandibular bone degeneration (Table 5.2). This
is novel as most studies have used the OVX model to focus on osteoporosis of weight
bearing regions [28-34]. Additionally, few studies have attempted treating mandible
defects with novel regenerative strategies. Leeuwen et al., 2012 created a 5 mm circular
defect in the mandibular angle and studied bone regeneration upon implanting
membranes composed of collagen, e-PTFE, or a novel, degradable membrane based
on poly-(trimethylene carbonate) (PTMC) [35]. It was found that all membrane-treated
defects progressively showed new bone formation over 12 weeks. Most recently, Cooke
et al., 2020 found that mandible defects treated with 3D-printed LayFomm scaffolds had
increased bone mass, greater trabecular thickness, and less trabecular separation in
comparison to mandibles that were treated with Norian CRS putty (a calcium phosphate
bone cement) [36]. In the OVX model, Jiang et al., 2017 found significant mandibular
condyle bone loss, which was in part inhibited by bisphosphonate treatment [37].
Similarly, we created a critical sized mandible defect in both normal adult rats and
osteoporotic rats. These defects were immediately filled with a 3D-printed rGO scaffold
to both support the defect and deliver stem cells, with the goal of stimulating new bone
differentiation. We chose a carbon-based, graphene material as it spontaneously
stimulates human MSCs into bone differentiation without any osteo-inductive reagents
[7, 8, 38]. This is important as a major goal is to develop bone regenerative treatments
that are both cost-effective and with limited side effects. Supportively, graphene
materials demonstrate ectopic osteogenesis in vivo, thereby confirming its
osteoinductivity at non-bony sites [39]. Finally, graphene materials are under study to
not only deliver exogenous stem cells, but also to attract endogenous stem cell
migration and differentiation at the injury site. If effective, this strategy would eliminate
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the regulatory concerns of stem cell therapies, thereby making graphene scaffolds more
clinically feasible.
To design a mandible scaffold, we successfully 3D-printed rGO constructs with
consistent morphology and porosity. In tissue engineering, 3D-printing technology is
revolutionizing personalized treatment, whereby scaffolds can be immediately produced
to match the dimensions of an injury site. Yet, many studies have opted to produce
graphene scaffolds by conventional foam techniques which limits consistent control of
morphology and porosity [40-45](MacDonald et al., in review). Creating highly porous
structures not only facilitates stem cell migration and attachment, but also allows blood
vessels to pass through the scaffold and support newly differentiating cells [46-48].
Following 3D-printing construction, we confirmed the rGO scaffold supported cell
attachment of human AD-MSCs. The rGO content was 0.5% which has the best
mechanical performance (i.e., compressive strength and stiffness) in comparison to
higher rGO concentrations at 1% and 3% [49]. Additionally, 0.5% rGO scaffolds
demonstrate good cytocompatibility, whereby human AD-MSCs proliferate and remain
viable over time [49]. These results are also encouraging as AD-MSCs are a preferred
clinical source of stem cells, being much easier to obtain than MSCs derived from bone
marrow.
On the day of surgery, rGO-cell constructs were implanted in mandible defects of both
sham and OVX rats. During treatment, all animals exhibited healthy behavior and no
signs of stress or infection. However, it should be noted that after 6 weeks, our Sprague
Dawley animals preferred standard chow over a soft-food diet. Nonetheless, this
indicates that animals could comfortably consume a hard-food diet, despite having a
mandible injury, which could reduce expenses in future studies.
After 60 days of treatment, the mandibles were harvested for further micro-CT and
histological evaluation. Micro-CT analysis showed that all defects had partial bone
regeneration when compared to the contralateral, non-defect side. Additionally, the
amount of new bone formation between normal adult rats and OVX rats was similar,
thereby suggesting rGO-cell constructs are useful in diseased, osteoporotic bone.
However, all rats received the same rGO-cell construct, therefore we cannot determine
if the new bone regeneration was due to the addition of rGO, AD-MSCs, or both.
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Additionally, the AD-MSCs were not tracked, so we could not distinguish between
exogenous and endogenous stem cell activity. However, we previously established that
MSCs derived from OVX animals lack normal osteogenic potential in comparison to
MSCs derived from healthy adult rats (MacDonald et al., in review). Therefore, it is
reasonable that implanting exogenous MSCs enhanced a signaling environment for
stem cell proliferation and differentiation [50, 51]. In the future, long-term studies are
needed to determine the maximum bone differentiation potential of rGO scaffolds, and
whether this process should be enhanced with other biological components.

CONCLUSIONS
Post-menopause osteoporotic women are at risk of experiencing traumatic fractures of
the mandible. In this study, we developed an osteoporotic rodent model with criticalsized mandible defects and investigated rGO-cell constructs as a candidate for
mandibular bone regeneration. We found that rGO-cell constructs supported new bone
regeneration of mandibular defects in both normal adult rats and osteoporotic rats, and
hence is a potential strategy for reconstructing traumatic jaw injuries. To our knowledge,
this is one of the first studies to (1) examine a bone regenerative treatment of
osteoporotic mandibles and (2) to test rGO scaffolds in maxillofacial bones. Materials
consisting of rGO should be further explored for bone regeneration of mandibular
fractures.
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APPENDIX
B

A

Cellink Biox6 3D Printer
C

D

E

Figure 5.1. 3D Printing of Scaffolds and Cell Attachment. (A) Image of Cellink Biox6 3D
Printer. (B) Image of printing 3D rGO scaffold. (C) Final rGO printed scaffold (top view) and (D)
side view; white artifacts are due to reflection of camera during photography. (E) Confocal
Image of AD-MSCs attached to rGO scaffold after 48 hr. Red fluorescence indicates cells
stained with DiI.
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A

B

Figure 5.2. Diagram of Surgical Procedure. (A) An incision was made at the
mandible area, followed by a circular defect at the mandibular angle. The defect was
then filled with AD-MSCs attached to an rGO scaffold, followed by suturing. (B) Image
of rat cadaver with a mandible defect.
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Figure 5.3. (A) Average consumption of low calcium diet between sham (n=6) and OVX (n=6)
animals prior to surgery (B) Final weight of sham and OVX animals on the day of surgery and
sacrifice; asterisk indicates statistical significance (p<0.05); error bars presented as SEM.
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Table 5.1. Micro-CT analysis of control mandibles (non-defect side) of sham animals
consuming either a standard chow diet or low calcium diet. Data presented is the average
total volume (TV), bone volume (BV), bone volume/total volume (BV/TV), apparent bone
mineral density (aBMD), tissue bone mineral density (tBMD), numbers of trabeculae (TB.N),
trabecular thickness (Tb.Th), trabecular separation (TB.Sp), and connective density.

Parameter
TV (mm3)
BV (mm3)
BV/TV
aBMD (mg HA/ccm)
tBMD (mg HA/ccm)
Tb.N (1/mm)
Tb.Th (mm)
Tb.Sp (mm)
Connective Density
(1/mm3)

Standard
Diet
0.9263
0.6252
0.6815
679.7347
975.9119
6.9581
0.1437
0.1657

Low Ca2+
Diet
0.9363
0.5762
0.6237
654.0386
1005.0615
6.5129
0.1399
0.1890

103.1047

93.8882

P-Value
0.9554
0.6121
0.2978
0.5601
0.0761
0.5573
0.5880
0.2984
0.6655

Data was analyzed using paired t-tests [n = 5 (standard diet) and 6 (low Ca2+ diet)
sham rats).

Table 5.2. Micro-CT analysis of control mandibles (non-defect side) between sham and
OVX animals. Data presented is the average total volume (TV), bone volume (BV), bone
volume/total volume (BV/TV), apparent bone mineral density (aBMD), tissue bone
mineral density (tBMD), numbers of trabeculae (TB.N), trabecular thickness (Tb.Th),
trabecular separation (TB.Sp), and connective density.

Parameter

Sham

OVX

P-value

TV (mm3)
BV (mm3)
BV/TV
aBMD (mg HA/ccm)
tBMD (mg HA/ccm)
Tb.N (1/mm)
Tb.Th (mm)
Tb.Sp (mm)
Connective Density
(1/mm3)

0.9363
0.5762
0.6237
654.0386
1005.0615
6.5129
0.1399
0.1890

1.2147
0.4388
0.3738
434.8285
978.8372
4.0157
0.1192
0.2906

0.3126
0.1909
0.0005
0.0003
0.0998
0.0002
0.0273
0.0030

93.8882

82.7074

0.4466

Data was analyzed using paired t-tests (n = 5 sham and 6 OVX rats).
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Table 5.3. Micro-CT results after comparing the average defect side: non-defect side of sham
and OVX animals. Data presented is the total volume (TV), bone volume (BV), bone
volume/total volume (BV/TV), apparent bone mineral density (aBMD), and tissue bone
mineral density (tBMD).

Parameter

Sham

OVX

P-value

TV (mm3)
BV (mm3)
BV/TV
aBMD (mg HA/ccm)
tBMD (mg HA/ccm)

1.00
0.32
0.32
0.24
1.06

0.99
0.38
0.39
0.29
0.98

0.3893
0.5918
0.5547
0.6867
0.0378

Data was analyzed using paired t-tests (n = 5 sham and 6 OVX rats).
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Figure 5.4. Average percentage of newly formed bone within the former
defects as measured by micro-CT. For each animal group, the left-sided mandible
(normal) served as a control to determine bone regeneration on the right-sided
mandible (defect), which was treated with an rGO-cell construct. (n = 5 sham and 6
OVX rats).
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Figure 5.5. Representative von Kossa – MacNeal’s tetrachrome staining images of
mandibular defects treated with rGO-cell constructs in sham (A-C) and OVX (D-F) animals.
(A/D) Image that includes all region of interest. (B/E) Region of mineralization, as indicated
by black arrows. (C/F) Region of cellular integration between original bone and defect site,
as indicated by red boxes. All images were taken under 10 X magnification.
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Figure 5.6. Representative Masson’s Trichrome staining images of mandibular defects
treated with rGO-cell constructs in sham (A-C) and OVX (D-F) animals. (A/D) Image that
includes all region of interest. (B/E) Region of cells undergoing differentiation, as indicated
by black arrows. (C/F) Region between original bone and defect site, as indicated by red
boxes. All images were taken under 10 X magnification.
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